Manganese-Catalyzed Synthesis of Monofluoroalkenes via C-H

Activation and C-F Cleavage

Sai-Hu Cai, Lu Ye, Ding-Xing Wang, Yi-Qiu Wang, Lin-Jie Lai, Chuan Zhu, Chao Feng,* and Teck-Peng Loh*

Supporting Information

Table of Contents

1. General information2
2. Experimental sections2
2.1 Substrate Synthesis2
2.2 Condition Optimization
3. General Method for the C-H α-fluoroalkenylation of arenes4
4. Mechanism Study
4.1 The Ration of <i>E/Z</i> Isomer Variation with Time7
4.2 Z isomer encounter standard condition7
4.3 Intermolecular Competition Experiments
4.4 Kinetic Isotope Effect9
4.5 Free Radical Scavengers10
4.6 C-H α-fluoroalkenylation of arenes with Cyclometalated Complex Mn-I
4.7 Control reactions between 1a and alkene, gem-dibromoalkene and terminal
bromofluoroolefins11
5. Characterization data for compounds14
6. References
7. ¹ H and ¹³ C NMR spectra

1. General information

Unless otherwise noted, all reagents and solvents were purchased from commercial suppliers and used without further purification. All reactions were carried out under Ar atmosphere. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C on Bruker Advance 400M NMR spectrometers (CDCl₃ as solvent). Chemical shifts for ¹H NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of SiMe₄ (δ 0.00 singlet). Multiplicities were given as: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); dt (doublet of triplets); m (multiplets) and etc. Coupling constants are reported as a *J* value in Hz. ¹³C NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of chloroform-d (δ 77.16 triplet). High resolution mass spectral analysis (HRMS) was performed on Waters-XEVOG2 Q-TOF (Waters Corporation). Flash chromatography was performed using 200-300 mesh silica gel with the indicated solvent system.

2. Experimental sections

2.1 Substrate Synthesis

1w was purchased from commercial supplier. Indole derivatives $1p-s^{1a}$, pyridine derivatives $1u^3$, $1v^4$ were prepared according to the reported methods.

2.1.1 General Method for Synthesis of 1-(Pyrimidin-2-yl)-1H-indoles and 1-(Pyrimidin-2-yl)-1H-pyrrole



General Method A: Following a previous procedure¹, an oven-dried round-bottom flask was charged with indole (1 equiv, 10 mmol) in DMF (0.5 M), following by portionwise adding of NaH (60% dispersion in mineral oil, 1.1 equiv, 11 mmol) at 0 °C. After sittring for 30 min at 0 °C, 2-chloropyrimidine (1.2 equiv, 12 mmol) was added in. The resulting mixture was stirred at 130 °C for 24 h. Then the mixture was cooled to room temperature, washed with water and extracted with EtOAc. The layers were separated and the organic layer was dried (Na2SO4), filtered and evaporated. Purification by column chromatography on silica gel or recrystallization using EtOAc/PE as the solvent. **2.1.2 General Method for Synthesis of** *gem*-Difluoroalkenes



General Method B: Following a previous procedure², to a 100 mL flame-dried round-bottom flask equipped with a stir-bar, (If R = Electron-Donating Group) Sodium 2-chloro-2,2-difluoroacetate (2 equiv, 40 mmol) was added in the mixture of corresponding aldehyde (1 equiv, 20 mmol) and triphenyl phosphine (2 equiv, 40 mmol) in NMP (0.5 M), the reaction was heated at 100 °C and kepted at this temperature until no further evolution of CO₂ was observed (about 5 min). Then water was added to the reaction slowly and the mixture was extracted with Et₂O or EtOAc, combined the organic layer and 10 mL H₂O₂ (30 wt% in water) was added to washed the organic layer, dried over Na₂SO₄. After evaporating solvent at cooled-water bath or room temperature, the residue was subjected to column chromatography on silica gel to deliver the product. [Note: If R = Electron-Withdrawing Group, F₂ClCCOONa (2 equiv) was portionwise added in the mixture of corresponding aldehyde (1 equiv) and PPh₃ (2 equiv) in NMP (0.5 M) which have heated at 100 °C.]

2.2 Condition Optimization

2.2.1 Optimization of solvent and additive



yield^a(E/Z)^b

1	-	Hexane	67% (73/27)	19	MgO (1.0 equiv)	Hexane	60%(72/28)
2	-	i-Pr ₂ O	54% (72/28)	20	KPF ₆ (0.5 equiv)	Hexane	83% (73/27)
3	-	n-Pr ₂ O	29% (71/29)	21	Zn (1.0 equiv)	Hexane/H ₂ O (2/1)	trace
4	-	Hexane/i-Pr ₂ O (2/1)	57% (73/27)	22	Zn (1.0 equiv)	Hexane (0.5 mL)	13%(61/39)
5	-	Hexane/n-Pr ₂ O (2/1)	52% (73/27)	22	Zn (1.0 equiv)	Hexane (3.0 mL)	53%(75/25)
6	Zn (0.5 equiv)	Hexane	59%(72/28)	23	Zn (1.0 equiv)	Cyclohexane	45% (70/30)
7	Zn (1.0 equiv)	Hexane	73% (73/27)	24	Zn (1.0 equiv)	Pentane	50% (72/28)
8	Zn (1.5 equiv)	Hexane	45%(72/28)	25	Zn (1.0 equiv)	Heptane	32% (70/30)
9	CuOAc (10 mol%)	Hexane	37% (72/28)	26	Zn (1.0 equiv)	HFIP	ndp
10	Cu(OAc) ₂ (10 mol%)	Hexane	42% (71/29)	27	Zn (1.0 equiv)	MeOH	ndp
11	18-Crown-6 (1.0 equiv) Hexane	ndp	28	Zn (1.0 equiv)	i-Pr ₂ O	40% (70/30)
12	Mn (1.0 equiv)	Hexane	42%(73/27)	29	Zn (1.0 equiv)	MeNO ₂	ndp
13	Fe (1.0 equiv)	Hexane	40%(68/32)	30(c)	KPF ₆ (50 mol%)	Hexane	60% (73/27)
14	ZnBr ₂ (1.0 equiv)	Hexane	22%(35/65)	31(c)	KPF ₆ (25 mol%)	Hexane	60% (73/27)
15	Ac-Phe-OH (1.0 equiv) Hexane	trace	32	KPF ₆ (1.2 equiv)	Hexane	71% (74/26)
16	AgOAc (1.0 equiv)	Hexane	trace	33(c)	AgPF ₆ (25 mol%)	Hexane	33% (73/27)
17	Ag ₂ CO ₃ (0.5 equiv)	Hexane	72%(72/28)	34(d)	KPF ₆ (50 mol%)	Hexane	trace
18	Ag ₂ O (0.5 equiv)	Hexane	66%(73/27)	35(e)	KPF ₆ (50 mol%)	Hexane	38% (76/24)

^aIsolated yield. ^bDetermined by ¹H NMR after flash column chromatography. ^cK₂CO₃ (25 mol%). ^dAir condition. ^eRun in 120°C.

2.2.2 Optimization of base and catalyst



entry	cat.	base	yield ^a (E/Z) ^b	entry	cat.	base	yield ^a (<i>E/Z</i>) ^b
1(c)	-	K ₂ CO ₃ (50 mol%)	nr	10	Mn ₂ (CO) ₁₀ (10 mol%)	K ₃ PO ₄ (50mol%)	57% (74/26)
2(d)	Mn ₂ (CO) ₁₀ (10 mol%)	-	49% (72/28)	11	Mn ₂ (CO) ₁₀ (10 mol%)	K ₃ PO ₃ ·3H ₂ O (50mol%)	60% (74/26)
3	Mn ₂ (CO) ₁₀ (5 mol%)	K ₂ CO ₃ (50 mol%)	49% (74/26)	12	Mn ₂ (CO) ₁₀ (10 mol%)	Et ₂ NH (50 mol%)	26% (66/34)
4	Mn ₂ (CO) ₁₀ (15 mol%)	K ₂ CO ₃ (50 mol%)	84% (73/27)	13(e)	MnBr(CO) ₅ (20 mol%)	K ₂ CO ₃ (50 mol%)	48% (73/27)
5	Mn ₂ (CO) ₁₀ (10 mol%)	K ₂ CO ₃ (25 mol%)	78% (73/27)	14	MnBr(CO) ₅ (20 mol%)	K ₂ CO ₃ (50 mol%)	60% (73/27)
6	Mn ₂ (CO) ₁₀ (10 mol%)	K ₂ CO ₃ (200 mol%)	64% (73/27)	15	MnBr(CO) ₅ (10 mol%)	K ₂ CO ₃ (50 mol%)	40% (74/26)
7	Mn ₂ (CO) ₁₀ (10 mol%)	KHCO3 (50 mol%)	68% (73/27)	16(e,f)	MnBr(CO) ₅ (20 mol%)	K ₂ CO ₃ (50 mol%)	56% (61/39)
8	Mn ₂ (CO) ₁₀ (10 mol%)	Na ₂ CO ₃ (50 mol%)	42% (72/28)	17(e,g)	Re ₂ (CO) ₁₀ (10 mol%)	K ₂ CO ₃ (50 mol%)	trace
9	Mn ₂ (CO) ₁₀ (10 mol%)	NaOAc (50 mol%)	24% (69/31)				

^aIsolated yield. ^bDetermined by ¹H NMR after flash column chromatography. ^cNo catalyst. ^dNo base. ^eNo additive (Zn). ^f1.5 equiv Me₂Zn as additive. ^g50 mol% KPF₆ as additive.

2.2.3 Optimization of additive to investigate the role of KPF6



^aIsolated yield. ^bDetermined by ¹H NMR after flash column chromatography. ^cno base. (Note: We obtained **3aa** in 20% isolated yield (*E/Z* 8/92) in Ackermann's reaction conditions (*ACS Catal.,* 2017, **7**, 4209-4213.), but 5 mol% Mn₂(CO)₁₀ instead of 10 mol% MnBr(CO)₅.)

3. General Method for the C-H α-fluoroalkenylation of arenes



General Method C: An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with 1 (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **3** (E/Z mixture).





3.2 Substrate Scope

3.2.1 Scope of indole derivatives in the C-H/C-F activation reaction



[a] Isolated yield. [b] Determined by ¹H NMR after flash column chromatography. [c] Isomer ration determined by ¹⁹F NMR after flash column chromatography. Ar = (p-COOMe)Ph.

3.2.2 Scope of *gem*-difluoroalkene for the *C*-*H*/*C*-*F* activation reaction



3.2.3 Incompetent substrate



4. Mechanism Study4.1 The Ration of *E/Z* Isomer Variation with Time



Five parallel reactions of 1a with 2a were performed to monitor the ration of E/Z isomer variation with time.

An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **1a** (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2a** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for especial time (1 h, 2 h, 4 h, 6 h, 8 h). After cooling to room temperature, the mixture was then filtered over silica gel. The filtrate was concentrated under reduced pressure to afford the crude products, the ration of **E/Z isomer** was determined by crude ¹H NMR.







- Following our previous procedure², an oven-dried 10 ml Schlenk tube was charged with **1a** (0.5 mmol), [RhCp*(CH₃CN)₃](SbF₆)₂ (4% mmol), **2a** (1.5 equiv) in sequence, followed by adding anhydrous MeOH (2.5 ml) through syringe and stirring at 80 °C for 16 h, then removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **Z-3aa** (white solid, 171.8mg, 92%).
- (2) An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with Z-3aa (0.15 mmol, 1 equiv), Mn₂(CO)₁₀ (0.015 mmol, 10 mol%), K₂CO₃ (0.075 mmol, 50 mol%), KPF₆ (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the product and determined by NMR (¹H NMR, ¹⁹F NMR) found trace E-3aa (E/Z 1/174).
- (3) An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with 1a (0.15 mmol, 1 equiv), 2d (0.3 mmol, 2 equiv), Z-3aa (0.15 mmol), Mn₂(CO)₁₀ (0.015 mmol, 10 mol%), K₂CO₃ (0.075 mmol, 50 mol%), KPF₆ (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, the mixture was then filtered over silica gel. The filtrate was concentrated under reduced pressure to afford the crude products, then determined by NMR (¹H NMR, ¹⁹F NMR) found 3ad (E/Z 15/85), Z-3aa (E/Z 0/100), E-3aa not detected.
- **4.3 Intermolecular Competition Experiments**
- 4.3.1 Between Indole Derivatives 1c and 1j



An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with 1c (0.15 mmol, 1 equiv), and 1j (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, 2a (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, the mixture was then filtered over silica gel. The filtrate was concentrated under reduced pressure to afford the crude products, the ration of 3ca/3ja was determined by ¹⁹F NMR.

4.3.2 Between gem-difluoroalkene 2a and 2b



An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **1a** (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2a** (0.3 mmol, 2 equiv), **2b** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, the mixture was then filtered over silica gel. The filtrate was concentrated under reduced pressure to afford the crude products, the ration of **3aa/3ab** was determined by ¹⁹F NMR.

4.4 Kinetic Isotope Effect

4.4.1^[5] Preparation of [D]-1a





4.4.2 Intermolecular KIE by Independent Experiments



Two parallel reactions of **2a** with **1a** and **[D]-1a** respectively were performed to determine the corresponding KIE value.

An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with 1a (0.15 mmol, 1 equiv), or

[D]-1a (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2a** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 1.5 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **3aa** (E/Z mixture).(Note: **1a** as substrate the isolated yield of **3aa** is 27.3 mg; [D]-**1a** as substrate the isolated yield of **3aa** is 25.5 mg)

4.5 Free Radical Scavengers



4.6 C-H α-fluoroalkenylation of arenes with Cyclometalated Complex Mn-I 4.6.1 Synthesis of Cyclometalated Complex Mn-I^[6]



An oven-dried 25 mL Schlenk tube equipped with a stirring bar was charged with **1a** (1 mmol, 1 equiv), MnBr(CO)₅ (1 mmol, 1 equiv) in sequence. After refilling with Ar repeated three times, dicyclohexylamine (2 mmol, 2 equiv) and 1,4-dioxane (2.0 mL) was added through syringe in sequence. The mixture was heated in 100 °C for 14 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography (TLC: 15% EtOAc/PE; column: 5%-20% DCM/PE) afforded the desired product **Mn-I** (yellow solid, 227.6 mg, 63%). ¹**H NMR (400 MHz, CDCl₃**): δ 8.72 (s, 1H), 8.64 – 8.45 (m, 2H), 7.45 (d, *J* = 7.5 Hz, 1H), 7.18 (d, *J* = 27.8 Hz, 2H), 6.84 (d, *J* = 34.1 Hz, 2H). ¹³**C NMR (101 MHz, CDCl₃**): δ 218.5, 213.2, 210.8, 162.4, 161.5, 161.0, 160.3, 138.6, 136.2, 123.1, 120.9, 119.5, 117.7, 114.2, 113.8. **HRMS (ESI, m/z):** calcd. for C₁₆H₈MnN₃O₄H [M+H]⁺ 361.9974, found 361.9981.

4.6.2 Cyclometalated Complex Mn-I as Catalyst



An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **1a** (0.15 mmol, 1 equiv), **Mn-I** (0.03 mmol, 20 mol%), K₂CO₃ (0.075 mmol, 50 mol%), KPF₆ (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2a** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe

in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **3aa** (yellow oil, 35.3 mg, 63%, E/Z 65/35).

4.6.3 Stoichiometric Reaction with Cyclometalated Complex Mn-I



An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **Mn-I** (0.15 mmol, 1 equiv), K₂CO₃ (0.075 mmol, 50 mol%), KPF₆ (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2a** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added through syringe in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **3aa** (yellow oil, 41.5 mg, 74%, E/Z 65/35).

4.7 Control reactions between 1a and alkene, *gem*-dibromoalkene^[7] and terminal bromofluoroolefins^[8]



An oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **1a** (0.15 mmol, 1 equiv), $Mn_2(CO)_{10}$ (0.015 mmol, 10 mol%), K_2CO_3 (0.075 mmol, 50 mol%), KPF_6 (0.075 mmol, 50 mol%) in sequence. After refilling with Ar repeated three times, **2m or 2n or 2o** (0.3 mmol, 2 equiv) and hexane (1.5 mL, 0.1 M) was added in sequence. The mixture was stirred at room temperature about 30 min and then heated in 140 °C for 15 h. After cooling to room temperature, the mixture was then filtered over silica gel. The filtrate was concentrated under reduced pressure, then determined the target product by TLC and crude ¹H NMR.

4.8 Study of the E/Z selectivity of the product



General procedure for the control experiments: an oven-dried 10 mL Schlenk tube equipped with a stirring bar was charged with **1a**, Mn₂(CO)₁₀/MnBr(CO)₅, K₂CO₃, NaOAc in sequence. After refilling with Ar repeated three times, **2a** and solvent was added through syringe in sequence. The mixture was stirred at room temperature about 30

min and then heated in the temperature as indicated in the scheme. After cooling to room temperature, removal of the solvent in vacuo and purification of the residue by silica gel column chromatography afforded the desired product **3aa**.

As shown above, when the reaction was performed in 1,4-dioxane Z isomer was always the major product with either Mn(0) (eqn 1) or Mn(I) (eqn 2) which is consistent with Ackermann's work. By contrast, the ratio of E isomer increased in the cases of hexane was used as solvent regardless of catalyst and additive (eqn 3 and 4) and the E/Z ratio of product was further improved in diluted solution (eqn 5). However, the choice of the solvent is quite important under less concentrated reaction conditions (eqn 6). In conclusion, the solvent plays a major role for the unusual E/Z selectivity in this reaction.

5. Characterization data for compounds

Methyl 4-(2-fluoro-2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3aa)



Following General Method C, **3aa** was obtained as yellow oil (0.125 mmol, 46.6 mg, 83%, *E/Z* 73/27) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.8 Hz, 2H), 8.49 (dd, *J* = 8.5, 0.9 Hz, 1H), 7.80 – 7.72 (m, 2H), 7.54 – 7.48 (m, 1H), 7.35 (ddt, *J* = 8.4, 7.2, 1.1 Hz, 1H), 7.25 – 7.17 (m, 3H), 7.08 (t, *J* = 4.8 Hz, 1H), 6.76 (dd, *J* = 3.6, 0.8 Hz, 1H), 6.44 (d, *J* = 17.9 Hz, 1H), 3.81 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.2, 157.5, 153.9 (d, *J* = 248.8 Hz), 139.2 (d, *J* = 11.0 Hz), 137.2 (d, *J* = 1.7 Hz), 129.7, 129.4, 128.7 (d, *J* = 1.4 Hz), 128.5 (d, *J* = 2.8 Hz), 128.5

(d, J = 0.9 Hz), 125.5 (d, J = 0.9 Hz), 122.7, 121.7, 117.4, 115.1, 113.3 (d, J = 5.9 Hz), 110.8 (d, J = 31.8 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -88.2 (dd, J = 17.8, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₆FN₃O₂H [M+H]⁺ 374.1305, found: 374.1308 Z isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, J = 4.8 Hz, 2H), 8.36 (dd, J = 8.4, 0.9 Hz, 1H), 8.04 – 7.94 (m, 2H), 7.66 – 7.57 (m, 3H), 7.34 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.16 (t, J = 4.8 Hz, 1H), 7.00 (dd, J = 2.5, 0.8 Hz, 1H), 6.29 (d, J = 35.7 Hz, 1H), 3.89 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.4, 157.7, 153.8 (d, J = 261.1 Hz), 138.6 (d, J = 4.5 Hz), 137.9, 132.0 (d, J = 25.5 Hz), 129.9, 128.8 (d, J = 8.0 Hz), 128.7 (d, J = 2.5 Hz), 128.5, 125.4, 122.8, 121.5, 117.8, 114.3, 111.8 (d, J = 5.6 Hz), 108.3(d, J = 9.7 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -96.7 (dd, J = 35.5, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₆FN₃O₂H [M+H]⁺ 374.1305, found: 374.1309.

Methyl 4-(2-fluoro-2-(4-methyl-1-(pyrimidin-2-yl)-1*H*-indol-2-yl)vinyl)benzoate (3ba)



Following General Method , **3ba** was obtained as yellow oil (0.113 mmol, 43.4 mg, 75%, *E/Z* 72/28) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, **CDCl**₃): δ 8.70 (d, *J* = 4.8 Hz, 2H), 8.31 (d, *J* = 8.5 Hz, 1H), 7.85 – 7.69 (m, 2H), 7.30 – 7.19 (m, 3H), 7.07 (t, *J* = 4.8 Hz, 1H), 7.04 – 6.99 (m, 1H), 6.83 (dd, *J* = 3.5, 0.8 Hz, 1H), 6.44 (d, *J* = 18.0 Hz, 1H), 3.82 (s, 3H), 2.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.2, 157.5, 154.0 (d, *J* = 249.2 Hz), 139.2, 139.0, 137.1 (d, *J* = 1.9 Hz), 131.3 (d, *J* = 1.0 Hz), 129.7, 129.0 (d, *J* = 28.2 Hz), 128.5, 128.5, 125.6 (d, *J* = 1.1 Hz), 123.0, 117.4, 112.6,

111.7 (d, J = 5.8 Hz), 110.7 (d, J = 31.5 Hz), 52.1, 18.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -87.5 (dd, J = 17.8, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1465. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.73 (d, J = 4.9 Hz, 2H), 8.16 (d, J = 8.4 Hz, 1H), 8.05 – 7.94 (m, 2H), 7.77 – 7.53 (m, 2H), 7.27 – 7.17 (m, 1H), 7.12 (t, J = 4.8 Hz, 1H), 7.07 – 6.97 (m, 2H), 6.29 (d, J = 35.6 Hz, 1H), 3.88 (s, 3H), 2.54 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.4, 157.7, 154.0 (d, J = 262.2 Hz), 138.7 (d, J = 4.4 Hz), 137.7, 131.4 (d, J = 24.6 Hz), 131.0, 129.9, 128.8 (d, J = 8.0 Hz), 128.3, 127.2, 125.6, 123.0, 117.7, 111.8, 110.3 (d, J = 6.0 Hz), 108.1 (d, J = 10.6 Hz), 52.2, 18.7. ¹⁹F NMR (376 MHz, CDCl₃): δ -96.58 (dd, J = 35.9, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1470.

Methyl 4-(2-fluoro-2-(4-methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ca)



Following General Method C, **3ca** was obtained as a yellow oil of inseparable *E/Z* mixture (0.138 mmol, 55.8 mg, 92%, *E/Z* 70/30) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.75 (dd, *J* = 18.3, 4.8 Hz, 2H), 8.14 – 7.76 (m, 3H), 7.67 – 6.91 (m, 5H), 6.66 (dd, *J* = 10.7, 7.9 Hz, 1H), 6.52 – 6.25 (m, 1H), 4.02 – 3.78 (m, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.4, 158.2, 156.4 (d, *J* = 260.7 Hz, *Z*), 156.3 (d, *J* = 250.0 Hz, *E*), 153.7, 153.5, 152.6, 152.5, 139.2 (d, *J* = 10.4 Hz), 138.8 (d, *J* = 4.4 Hz), 138.5 (d, *J* = 1.9 Hz), 130.6 (d, *J* = 25.0 Hz), 129.9, 129.7, 128.8 (d, *J* = 8.1 Hz), 128.6, 128.5 (d, *J* = 2.8 Hz), 128.4 (d, *J* = 1.3 Hz), 128.1 (d, *J* = 28.1 Hz), 126.5 (d, *J* = 1.1 Hz), 126.4, 119.5 (d, *J* = 1.6

Hz), 119.3, 117.8, 117.5, 110.7, 110.5, 110.5, 110.4, 109.0 (d, J = 6.0 Hz), 108.0, 107.9, 107.2, 102.6, 102.5, 55.6, 55.5, 52.2, 52.1. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, 3.7 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -87.6 (dd, J = 17.8, δ -87.6

Methyl 4-(2-fluoro-2-(5-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3da)



Following General Method C, **3da** was obtained as yellow oil (0.123 mmol, 47.4 mg, 82%, *E/Z* 74/26) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 4.8 Hz, 2H), 8.41 (d, *J* = 8.6 Hz, 1H), 7.84 – 7.71 (m, 2H), 7.31 (dt, *J* = 1.8, 0.8 Hz, 1H), 7.26 – 7.21 (m, 2H), 7.21 – 7.16 (m, 1H), 7.08 (t, *J* = 4.8 Hz, 1H), 6.70 (dd, *J* = 3.6, 0.8 Hz, 1H), 6.45 (d, *J* = 17.8 Hz, 1H), 3.83 (s, 3H), 2.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.2, 157.5, 154.1 (d, *J* = 248.6 Hz), 139.3 (d, *J* = 10.5 Hz), 135.5 (d, *J* = 2.0 Hz), 132.2, 129.7, 129.5 (d, *J* = 28.0

Hz), 128.9 (d, J = 1.6 Hz), 128.5 (d, J = 2.9 Hz), 128.4 (d, J = 1.0 Hz), 127.1 (d, J = 1.2 Hz), 121.4, 117.2, 114.9, 113.1 (d, J = 5.7 Hz), 110.5 (d, J = 31.8 Hz), 52.1, 21.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -87.8 (dd, J = 18.0, 3.7 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1460. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, J = 4.8 Hz, 2H), 8.28 (d, J = 8.6 Hz, 1H), 8.08 – 7.96 (m, 2H), 7.70 – 7.60 (m, 2H), 7.25 (s, 1H), 7.21 – 7.13 (m, 2H), 6.95 (d, J = 2.4 Hz, 1H), 6.30 (d, J = 35.6 Hz, 1H), 3.92 (s, 3H), 2.46 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.3, 157.7, 154.0 (d, J = 264.7 Hz), 138.7 (d, J = 4.5 Hz), 136.2, 132.2, 132.9 (d, J = 24.7 Hz), 129.9, 128.8, 128.7, 127.0, 121.2, 117.5, 114.1, 111.7 (d, J = 5.6 Hz), 108.1 (d, J = 10.5 Hz), 52.2, 21.5. ¹⁹F NMR (376 MHz, CDCl₃): δ -96.3 (dd, J = 35.7, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1461, found: 388.1467.

Methyl 4-(2-fluoro-2-(5-methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ea)



Following General Method C, **3ea** was obtained as yellow oil (0.092 mmol, 36.8 mg, 61%, *E/Z* 73/27) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 4.8 Hz, 2H), 8.47 (d, *J* = 9.1 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.32 – 7.20 (m, 2H), 7.10 (t, *J* = 4.8 Hz, 1H), 7.02 (ddd, *J* = 9.1, 2.6, 1.0 Hz, 1H), 6.98 (d, *J* = 2.6 Hz, 1H), 6.72 (dd, *J* = 3.5, 0.8 Hz, 1H), 6.48 (d, *J* = 17.7 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 158.2, 157.4, 155.9, 154.0 (d, *J* = 249.1 Hz), 139.2 (d, *J* = 11.0 Hz), 132.1 (d, *J* = 2.0

Hz), 129.9 (d, J = 27.7 Hz), 129.7, 129.4 (d, J = 1.4 Hz), 128.5 (d, J = 2.8 Hz), 117.2, 116.3, 115.3, 115.3, 113.1 (d, J = 5.9 Hz), 110.7 (d, J = 31.0 Hz), 103.1, 55.8, 52.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -87.8 (dd, J = 17.6, 3.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₃H [M+H]⁺ 404.1410, found: 404.1416. *Z* isomer: ¹H NMR (400

MHz, CDCl₃): δ 8.72 (d, J = 4.8 Hz, 2H), 8.30 (d, J = 9.1 Hz, 1H), 8.04 – 7.94 (m, 2H), 7.70 – 7.56 (m, 2H), 7.12 (t, J = 4.8 Hz, 1H), 7.05 (d, J = 2.5 Hz, 1H), 6.98 (dd, J = 9.1, 2.6 Hz, 1H), 6.92 (d, J = 2.3 Hz, 1H), 6.27 (d, J = 35.5 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H). ¹³C **NMR (101 MHz, CDCl₃):** δ 167.0, 158.3, 157.6, 156.0, 153.8 (d, J = 262.7 Hz), 138.7 (d, J = 4.5 Hz), 132.8, 132.4 (d, J = 25.0 Hz), 129.9, 129.2, 128.8 (d, J = 8.0 Hz), 128.6 (d, J = 2.5 Hz), 117.5, 115.5, 115.1, 111.7 (d, J = 5.5 Hz), 108.3 (d, J = 9.8 Hz), 103.0, 55.8, 52.2. ¹⁹F **NMR (376 MHz, CDCl₃):** δ -96.2 (dd, J = 35.5, 2.6 Hz, 1F). **HRMS (ESI, m/z):** calcd. for C₂₃H₁₈FN₃O₃H [M+H]⁺ 404.1410, found: 404.1410.

Methyl 4-(2-fluoro-2-(6-methoxy-1-(pyrimidin-2-yl)-1*H*-indol-2-yl)vinyl)benzoate (3fa)



Following General Method C, **3fa** was obtained as yellow oil (0.120 mmol, 48.7 mg, 80%, *E/Z* 69/31) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* **isomer:** ¹H NMR (400 MHz, CDCl₃): δ 8.74 (d, *J* = 4.8 Hz, 2H), 8.14 (d, *J* = 2.2 Hz, 1H), 7.87 - 7.74 (m, 2H), 7.43 (d, *J* = 8.6 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.11 (t, *J* = 4.8 Hz, 1H), 6.91 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.75 (dd, *J* = 3.6, 0.7 Hz, 1H), 6.44 (d, *J* = 17.7 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.8, 158.2, 157.6, 154.1 (d, *J* = 249.0 Hz), 139.4 (d, *J* = 10.8 Hz), 138.3 (d, *J* = 1.9

Hz), 129.6, 128.6, 128.5 (d, J = 3.0 Hz), 128.3, 122.7 (d, J = 1.5 Hz), 122.2, 117.2, 113.5 (d, J = 5.8 Hz), 112.3, 110.2 (d, J = 32.7 Hz), 99.0, 55.8, 52.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -87.5 (dd, J = 17.7, 3.8 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₃H [M+H]⁺ 404.1410, found: 404.1413. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.08 – 7.91 (m, 3H), 7.64 (d, J = 8.2 Hz, 2H), 7.52 (d, J = 8.6 Hz, 1H), 7.18 (t, J = 4.8 Hz, 1H), 7.02 – 6.83 (m, 2H), 6.28 (d, J = 35.6 Hz, 1H), 3.92 (s, 3H), 3.90 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.8, 158.3, 157.8, 154.0 (d, J = 262.0 Hz), 139.0, 138.9 (d, J = 4.3 Hz), 131.9 (d, J = 24.3 Hz), 129.9, 128.7 (d, J = 8.1 Hz), 128.5 (d, J = 2.5 Hz), 122.6, 122.0, 117.6, 112.4, 112.0 (d, J = 5.5 Hz), 107.5 (d, J = 10.3 Hz), 98.3, 55.8, 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -96.2 (dd, J = 35.9, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₃H [M+H]⁺ 404.1410, found: 404.1419.

Methyl 4-(2-fluoro-2-(7-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ga)



Following General Method C, **3ga** was obtained as yellow oil (0.105 mmol, 40.4 mg, 70%, *E/Z* 72/28) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 10% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, **CDCl3**): δ 8.82 (d, *J* = 4.9 Hz, 2H), 7.93 – 7.79 (m, 2H), 7.49 (dd, *J* = 7.3, 1.8 Hz, 1H), 7.35 – 7.24 (m, 3H), 7.22 – 7.10 (m, 2H), 6.82 (d, *J* = 3.5 Hz, 1H), 6.48 (d, *J* = 18.1 Hz, 1H), 3.89 (s, 3H), 2.13 (s, 3H). ¹³C NMR (101 MHz, CDCl3): δ 166.9, 158.3, 158.1, 152.5 (d, *J* = 249.6 Hz), 138.3 (d, *J* = 10.9 Hz), 136.6 (d, *J* = 1.6 Hz), 130.7 (d, *J* = 27.3 Hz), 129.7, 128.8 (d, *J* = 1.4 Hz), 128.6 (d, *J* = 1.4 Hz), 128.5 (d, *J* = 3.0 Hz), 127.8, 122.9 (d, *J* = 0.9 Hz), 122.1, 119.8, 119.5, 113.1 (d, *J* = 31.9 Hz), 110.7 (d, *J* = 5.3 Hz), 52.1, 20.6. ¹⁹F NMR (376

MHz, CDCl₃): δ -87.8 (dd, J = 18.1, 3.5 Hz, 1F). **HRMS (ESI, m/z):** calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1469. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.90 (d, J = 4.8 Hz, 2H), 8.00 – 7.92 (m, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.52 – 7.45 (m, 2H), 7.42 (t, J = 4.9 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 7.08 – 6.98 (m, 2H), 6.16 (d, J = 37.5 Hz, 1H), 3.91 (s, 3H), 1.96 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 159.5, 158.6, 152.6 (d, J = 260.7 Hz), 138.1 (d, J = 4.0 Hz), 137.9, 133.0 (d, J = 27.7 Hz), 129.9, 128.8, 128.7, 128.4, 127.5, 122.2, 122.0, 120.4, 119.6, 109.0 (d, J = 9.3 Hz), 108.5 (d, J = 4.8 Hz), 52.2, 19.7. ¹⁹F NMR (376 MHz, CDCl₃): δ -102.9 (d, J = 37.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1468.

Methyl 4-(2-fluoro-2-(3-methyl-1-(pyrimidin-2-yl)-1*H*-indol-2-yl)vinyl)benzoate (3ha)



Following General Method C, **3ha** was obtained as yellow oil (0.089 mmol, 34.2 mg, 59%, *E/Z* 66/34) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, *J* = 4.8 Hz, 2H), 8.63 (d, *J* = 8.5 Hz, 1H), 7.98 – 7.74 (m, 2H), 7.55 (dd, *J* = 7.8, 1.1 Hz, 1H), 7.43 (ddt, *J* = 8.3, 7.0, 1.2 Hz, 1H), 7.35 – 7.22 (m, 3H), 7.10 (t, *J* = 4.8 Hz, 1H), 6.62 (d, *J* = 17.2 Hz, 1H), 3.86 (s, 3H), 1.99 (d, *J* = 3.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.2, 157.7, 153.4 (d, *J* = 250.6 Hz), 139.4 (d, *J* = 11.3 Hz), 137.0 (d, *J* = 1.9 Hz), 129.9 (d, *J* = 1.5 Hz), 129.8, 128.3 (d, *J* = 1.4 Hz),

128.0 (d, J = 2.7 Hz), 126.4 (d, J = 25.4 Hz), 125.8 (d, J = 1.4 Hz), 122.3, 120.9 (d, J = 7.0 Hz), 120.0 (d, J = 1.3 Hz), 116.9, 115.3 (d, J = 1.1 Hz), 111.6 (d, J = 32.1 Hz), 52.1, 9.5 (d, J = 1.9 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -86.8 (dq, J = 17.1, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1464. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.74 (d, J = 4.8 Hz, 2H), 8.47 (d, J = 8.4 Hz, 1H), 8.11 – 7.98 (m, 2H), 7.67 (dd, J = 16.0, 8.1 Hz, 3H), 7.47 – 7.36 (m, 1H), 7.33 – 7.27 (m, 1H), 7.12 (t, J = 4.8 Hz, 1H), 6.09 (d, J = 36.1Hz, 1H), 3.93 (s, 3H), 2.51 (d, J = 2.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.2, 157.7, 152.3 (d, J = 262.9 Hz), 138.7 (d, J = 4.5 Hz), 136.8, 130.0, 128.8 (d, J = 8.1 Hz), 128.6 (d, J = 2.1 Hz), 128.1, 127.8, 125.8, 122.4, 120.4 (d, J = 5.9 Hz), 119.9, 117.1, 114.6, 110.8 (d, J = 10.6 Hz), 52.2, 10.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -91.6 (dt, J = 36.1, 3.2 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₈FN₃O₂H [M+H]⁺ 388.1461, found: 388.1470.

Methyl 4-(2-(4-chloro-1-(pyrimidin-2-yl)-1*H*-indol-2-yl)-2-fluorovinyl)benzoate (3ia)



Following General Method C, **3ia** was obtained as a yellow oil of inseparable *E/Z* mixture (0.090 mmol, 36.9 mg, 60%, *E/Z* 70/30) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.76 (dd, *J* = 19.6, 4.8 Hz, 2H), 8.48 – 8.21 (m, 1H), 8.10 – 7.76 (m, 2H), 7.69 – 6.86 (m, 6H), 6.52 (d, *J* = 17.9 Hz, 0.7H, *E*), 6.38 (d, *J* = 35.7 Hz, 0.3H, *Z*), 3.92 (s, 0.9H, *Z*), 3.86 (s, 2.1H, *E*). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 166.9, 158.5, 158.3, 157.4, 157.2, 153.1 (d, *J* = 261.9 Hz, *Z*), 153.1 (d, *J* = 248.8 Hz, *E*), 138.7, 138.6, 138.3, 138.3, 137.7 (d, *J* = 2.0 Hz), 132.6 (d, *J* = 24.5 Hz), 130.2 (d, *J* = 28.7 Hz), 130.0, 129.7, 128.9, 128.9, 128.8, 128.7 (d, *J* = 1.1 Hz), 128.5 (d, *J* = 2.9 Hz), 127.5 (d, *J* = 1.5 Hz),

127.4, 126.9 (d, J = 1.3 Hz), 126.6, 126.0 (d, J = 0.7 Hz), 125.9, 122.4, 118.2, 117.9, 113.7, 112.9, 111.4 (d, J = 31.2 Hz), 111.0 (d, J = 5.9 Hz), 109.5 (d, J = 5.2 Hz), 109.0 (d, J = 10.0 Hz), 52.2, 52.1. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -88.9 (dd, J = 18.0, 3.5 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -97.7 (dd, J = 35.7, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅ClFN₃O₂H [M+H]⁺ 408.0915, found: 408.0917.

Methyl 2-(1-fluoro-2-(4-(methoxycarbonyl)phenyl)vinyl)-1-(pyrimidin-2-yl)-1H-indole-4- carboxylate (3ja)



Following General Method C, **3ja** was obtained as a yellow solid of inseparable *E/Z* mixture (0.083 mmol, 35.5 mg, 55%, *E/Z* 68/32) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.95 – 8.51 (m, 3H), 8.07 – 7.97 (m, 1H), 7.86 – 7.37 (m, 4H), 7.28 – 7.14 (m, 3H), 6.60 – 6.37 (m, 1H), 4.14 – 3.65 (m, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 167.4, 167.2, 167.0, 166.9, 158.5, 158.3, 157.2, 153.4 (d, *J* = 252.2 Hz, *Z*), 153.2 (d, *J* = 248.9 Hz, *E*), 138.7, 138.6, 138.4, 137.7 (d, *J* = 1.5 Hz), 131.5, 131.2, 130.0, 129.7, 128.9 (d, *J* = 8.2 Hz), 128.6 (d, *J* = 1.0 Hz), 128.5 (d, *J* = 3.0 Hz), 128.3 (d, *J* = 1.1 Hz), 125.8, 124.7, 124.6, 122.7, 122.3, 119.7, 118.9, 118.2, 117.9, 113.6 (d, *J* = 5.2 Hz), 112.0 (d, *J* = 5.7 Hz), 111.4

(d, *J* = 31.0 Hz), 109.1 (d, *J* = 8.9 Hz), 52.3, 52.1, 52.1. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -88.9 (dd, *J* = 18.3, 3.4 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -98.1 (dd, *J* = 35.7, 2.4 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₈FN₃O₄H [M+H]⁺ 432.1360, found: 432.1366.

Methyl 4-(2-fluoro-2-(5-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ka)



Following General Method C, **3ka** was obtained as yellow oil (0.090 mmol, 35.4 mg, 60%, *E/Z* 72/28) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.74 (d, *J* = 4.8 Hz, 2H), 8.52 (dd, *J* = 9.2, 4.6 Hz, 1H), 7.89 – 7.75 (m, 2H), 7.27 – 7.22 (m, 2H), 7.19 (dd, *J* = 8.6, 2.7 Hz, 1H), 7.16 – 7.09 (m, 2H), 6.74 (dd, *J* = 3.5, 0.7 Hz, 1H), 6.51 (d, *J* = 17.7 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 159.2 (d, *J* = 239.2 Hz), 158.3, 157.3, 153.4 (d, *J* = 249.3 Hz), 139.0 (d, *J* = 10.9 Hz), 133.6 (d, *J* = 1.7 Hz), 131.0 (d, *J* = 28.0 Hz), 129.7, 129.3

(d, J = 1.1 Hz), 129.2 (d, J = 1.2 Hz), 128.5 (d, J = 2.8 Hz), 117.6, 116.5 (d, J = 8.8 Hz), 113.6 (d, J = 25.3 Hz), 112.8 (m), 111.0 (d, J = 30.3 Hz), 106.6 (d, J = 24.2 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -88.8 (dd, J = 17.8, 3.5 Hz, 1F), -121.0 (td, J = 9.0, 4.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅F₂N₃O₂H [M+H]⁺ 392.1211, found: 392.1218. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.77 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 9.2, 4.5 Hz, 1H), 8.09 – 7.94 (m, 2H), 7.72 – 7.58 (m, 2H), 7.33 – 7.24 (m, 1H), 7.19 (t, J = 4.8 Hz, 1H), 7.10 (td, J = 9.1, 2.6 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.32 (d, J = 35.6 Hz, 1H), 3.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 159.3 (d, J = 239.1 Hz), 158.4, 157.4, 153.4 (d, J = 262.5 Hz), 138.4 (d, J = 4.5 Hz), 134.2, 133.4 (d, J = 25.1 Hz), 129.9, 129.2 (d, J = 10.2 Hz), 128.8 (d, J = 8.0 Hz), 128.8 (d, J = 2.3 Hz), 117.9, 115.7 (d, J = 9.0 Hz), 113.5 (d, J = 25.4 Hz), 111.2 (m), 108.8 (d, J = 9.3 Hz), 106.4 (d, J = 23.8 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -97.0 (dd, J = 35.5, 2.5 Hz, 1F), -121.0 (td, J = 9.0, 4.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅F₂N₃O₂H [M+H]⁺ 392.1211, found: 392.1213.

Methyl 4-(2-(5-bromo-1-(pyrimidin-2-yl)-1*H*-indol-2-yl)-2-fluorovinyl)benzoate (3la)



Following General Method C, **3la** was obtained as yellow oil (0.093 mmol, 42.3 mg, 62%, *E/Z* 70/30) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 4.8 Hz, 2H), 8.40 (d, *J* = 9.0 Hz, 1H), 7.82 – 7.75 (m, 2H), 7.64 (d, *J* = 2.0 Hz, 1H), 7.43 (ddd, *J* = 9.0, 2.0, 0.9 Hz, 1H), 7.24 – 7.18 (m, 2H), 7.13 (t, *J* = 4.8 Hz, 1H), 6.68 (dd, *J* = 3.5, 0.8 Hz, 1H), 6.48 (d, *J* = 17.7 Hz, 1H), 3.83 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 158.3, 157.2, 153.2 (d, *J* = 249.2 Hz), 138.9 (d, *J* = 10.4 Hz), 135.8 (d, *J* = 1.6 Hz), 130.7 (d, *J* = 27.6 Hz), 130.3

(d, J = 1.3 Hz), 130.0, 129.7, 128.7 (d, J = 1.0 Hz), 128.5 (d, J = 2.8 Hz), 128.3 (d, J = 0.9 Hz), 124.1, 117.7, 116.8, 115.9, 112.2 (d, J = 5.7 Hz), 111.3 (d, J = 30.8 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -89.2 (dd, J = 17.8, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅BrFN₃O₂H [M+H]⁺ 452.0410, found: 452.0418. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.79 (d, J = 4.9 Hz, 2H), 8.29 (d, J = 8.9 Hz, 1H), 8.12 – 7.94 (m, 2H), 7.78 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.44 (dd, J = 9.0, 2.0 Hz, 1H), 7.21 (t, J = 4.8 Hz, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.33 (d, J = 35.5 Hz, 1H), 3.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 158.5, 157.4, 153.2 (d, J = 262.7 Hz), 138.4 (d, J = 5.4 Hz), 136.5, 133.1 (d, J = 25.0 Hz), 130.2, 128.9, 128.9, 128.8, 128.2, 123.9, 118.0, 116.0, 115.9, 110.6 (d, J = 5.6 Hz), 108.9 (d, J = 9.7 Hz), 52.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -97.2 (dd, J = 35.6, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅BrFN₃O₂H [M+H]⁺ 452.0410, found: 452.0414.

Methyl 2-(1-fluoro-2-(4-(methoxycarbonyl)phenyl)vinyl)-1-(pyrimidin-2-yl)-1H-indole-5-carboxylate (3ma)



Following General Method C, **3ma** was obtained as yellow oil (0.090 mmol, 38.9 mg, 60%, *E/Z* 67/33) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, *J* = 4.8 Hz, 2H), 8.53 (d, *J* = 8.9 Hz, 1H), 8.30 (d, *J* = 1.6 Hz, 1H), 8.07 (dt, *J* = 8.9, 1.1 Hz, 1H), 7.88 – 7.77 (m, 2H), 7.28 – 7.22 (m, 2H), 7.19 (t, *J* = 4.8 Hz, 1H), 6.86 (dd, *J* = 3.5, 0.7 Hz, 1H), 6.53 (d, *J* = 17.8 Hz, 1H), 3.94 (s, 3H), 3.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.5, 166.9, 158.4, 157.2, 153.1 (d, *J* = 251.4 Hz), 139.6 (d, *J*

= 1.5 Hz), 138.8 (d, J = 10.9 Hz), 131.1 (d, J = 29.8 Hz), 129.7, 128.7 (d, J = 0.7 Hz), 128.6 (d, J = 3.0 Hz), 128.3 (d, J = 1.3 Hz), 126.5, 124.7, 124.2, 118.0, 114.8, 113.6 (d, J = 6.0 Hz), 111.4 (d, J = 30.5 Hz), 52.2, 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -89.5 (dd, J = 17.8, 3.5 Hz). HRMS (ESI, m/z): calcd. for C₂₄H₁₈FN₃O₄H [M+H]⁺ 432.1360, found: 432.1364. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.82 (d, J = 4.9 Hz, 2H), 8.45 – 8.35 (m, 2H), 8.11 – 7.98 (m, 3H), 7.75 – 7.58 (m, 2H), 7.24 (d, J = 4.8 Hz, 1H), 7.10 (d, J = 2.3 Hz, 1H), 6.36 (d, J = 35.6 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.6, 166.9, 158.6, 157.3, 153.1 (d, J = 261.4 Hz), 140.2, 138.3 (d, J = 4.6 Hz), 133.4 (d, J = 25.2 Hz), 130.0, 128.9, 128.8, 128.2, 126.5, 124.8, 124.0, 118.3, 114.0, 111.9 (d, J = 5.3 Hz), 109.0 (d, J = 9.5 Hz), 52.3, 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -97.6 (dd, J = 35.9, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₈FN₃O₄H [M+H]⁺ 432.1360, found: 432.1370.

Methyl 4-(2-fluoro-2-(6-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3na)



Following General Method C, **3na** was obtained as yellow oil (0.098 mmol, 38.4 mg, 65%, *E/Z* 69/31) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, *J* = 4.8 Hz, 2H), 8.32 (dd, *J* = 10.9, 2.4 Hz, 1H), 7.88 – 7.75 (m, 2H), 7.47 (dd, *J* = 8.7, 5.5 Hz, 1H), 7.30 – 7.21 (m, 2H), 7.15 (t, *J* = 4.8 Hz, 1H), 7.01 (td, *J* = 8.9, 2.4 Hz, 1H), 6.76 (dd, *J* = 3.7, 0.8 Hz, 1H), 6.49 (d, *J* = 17.6 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 161.7 (d, *J* = 241.2 Hz), 158.3, 157.3, 153.6 (d, *J* = 248.9 Hz), 139.1 (d, *J* = 11.0 Hz), 137.4 (dd, *J* = 13.2, 1.6

Hz), 130.2 (d, J = 4.6 Hz), 129.9 (d, J = 4.6 Hz), 129.7, 128.5 (d, J = 2.8 Hz), 125.0, 122.5 (d, J = 10.0 Hz), 117.6, 113.1 (dd, J = 6.0, 1.0 Hz), 111.5 (d, J = 24.9 Hz), 110.8 (d, J = 31.1 Hz), 102.5 (d, J = 28.9 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCI₃): δ -88.2 (dt, J = 17.7, 3.0 Hz, 1F), -113.18 – -119.34 (m, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅F₂N₃O₂H [M+H]⁺ 392.1211, found: 392.1217. *Z* isomer: ¹H NMR (400 MHz, CDCI₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.17 (dd, J = 10.7, 2.4 Hz, 1H), 8.08 – 7.97 (m, 2H), 7.69 – 7.60 (m, 2H), 7.56 (dd, J = 8.6, 5.5 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 7.09 – 6.94 (m, 2H), 6.29 (d, J = 35.5 Hz, 1H), 3.92 (s, 3H). ¹³C NMR (101 MHz, CDCI₃): δ 167.0, 161.7 (d, J = 241.2 Hz), 158.4, 157.5, 153.5 (d, J = 262.3 Hz), 138.6 (d, J = 4.4 Hz), 138.1 (d, J = 129.1 Hz), 130.0, 129.7, 128.8, 128.7, 124.9 (d, J = 1.1 Hz), 122.3 (d, J = 10.2 Hz), 117.9, 111.6 (m), 111.4, 108.3 (d, J = 9.4Hz), 101.8 (d, J = 28.3 Hz), 52.3. ¹⁹F NMR (376 MHz, CDCI₃): δ -96.4 (dd, J = 35.6, 2.6 Hz, 1F), -115.6 (td, J =9.9, 5.4 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅F₂N₃O₂H [M+H]⁺ 392.1211, found: 392.1214.

Methyl 4-(2-(6-bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)-2-fluorovinyl)benzoate (30a)



Following General Method C, **30a** was obtained as yellow oil (0.107 mmol, 48.2 mg, 71%, *E/Z* 69/31) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.77 (d, *J* = 4.8 Hz, 3H), 7.87 – 7.77 (m, 2H), 7.45 – 7.32 (m, 2H), 7.30 – 7.21 (m, 2H), 7.17 (t, *J* = 4.8 Hz, 1H), 6.75 (dd, *J* = 3.5, 0.8 Hz, 1H), 6.51 (d, *J* = 17.8 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 158.4, 157.2, 153.3 (d, *J* = 248.7 Hz), 138.9 (d, *J* = 10.8 Hz), 137.7 (d, *J* = 1.8 Hz), 130.2 (d, *J* = 28.3 Hz), 129.7, 128.6 (d, *J* = 0.9 Hz), 128.5 (d, *J* = 3.0 Hz), 127.4 (d, *J* = 1.2 Hz),

126.1, 122.8, 119.4 (d, J = 1.5 Hz), 118.3, 117.8, 112.9 (d, J = 5.9 Hz), 111.1 (d, J = 30.7 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -88.87 - -89.30 (m, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅BrFN₃O₂H [M+H]⁺ 452.0410, found: 452.0414. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.80 (d, J = 4.8 Hz, 2H), 8.69 - 8.52 (m, 1H), 8.03 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 8.4, 1.8 Hz, 1H), 7.22 (t, J = 4.8 Hz, 1H), 6.99 (d, J = 2.3 Hz, 1H), 6.32 (d, J = 35.5 Hz, 1H), 3.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 158.5, 157.3, 153.3 (d, J = 262.7 Hz), 138.4 (d, J = 5.5 Hz), 132.6 (d, J = 24.7 Hz), 130.0, 129.7, 128.9 (d, J = 8.0 Hz), 128.8 (d, J = 2.4 Hz), 127.4, 126.1, 122.5, 119.1, 118.1, 117.5, 111.4 (d, J = 5.6 Hz), 108.8 (d, J = 9.7 Hz), 52.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -97.1 (dd, J = 35.5, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₅BrFN₃O₂H [M+H]⁺ 452.0410, found: 452.0416.

Methyl 4-(2-fluoro-2-(1-(pyridin-2-yl)-1*H*-indol-2-yl)vinyl)benzoate (3pa)



Following General Method C, **3pa** was obtained as a colourless oil of inseparable *E/Z* mixture (0.093 mmol, 34.4 mg, 62%, *E/Z* 61/39) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.76 – 8.45 (m, 1H), 8.04 – 7.85 (m, 1H), 7.82 – 7.43 (m, 5H), 7.40 – 7.26 (m, 2H), 7.24 – 6.90 (m, 4H), 6.56 – 5.91 (m, 1H), 3.89 (d, *J* = 16.5 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 152.7 (d, *J* = 260.1 Hz, *Z isomer*), 152.4 (d, *J* = 248.1 Hz, *E isomer*), 151.7, 150.8, 149.7, 149.4, 138.9, 138.6, 138.2, 138.1, 138.1, 138.1, 137.5 (d, *J* = 1.9 Hz), 131.9 (d, *J* = 30.4 Hz), 129.9, 129.7, 129.5 (d, *J* = 31.4 Hz), 128.8, 128.8, 128.7, 128.5 (d, *J* = 2.9 Hz), 127.9 (d, *J* = 1.3 Hz), 127.8, 124.8, 124.8, 122.7, 121.9, 121.8, 121.6, 120.8, 119.7,

112.5, 112.1, 111.7, 111.3, 110.0 (d, J = 4.4 Hz), 109.1 (d, J = 9.5 Hz), 108.3 (d, J = 4.7 Hz), 52.2, 52.2. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -89.1 (dd, J = 18.0, 2.8 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -102.9 (d, J = 37.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₁₇FN₂O₂H [M+H]⁺ 373.1352, found: 373.1360.

Methyl 4-(2-fluoro-2-(4-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3qa)



Following General Method C, **3qa** was obtained as a yellow oil of inseparable *E/Z* mixture (0.090 mmol, 36.5 mg, 60%, *E/Z* 68/32) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.74 – 8.65 (m, 0.32H, *Z isomer*), 8.53 (ddd, *J* = 4.9, 1.9, 0.8 Hz, 0.68H, *E isomer*), 8.02 – 7.97 (m, 0.67H, *Z isomer*), 7.91 (td, *J* = 7.8, 2.0 Hz, 0.33H, *Z isomer*), 7.84 – 7.78 (m, 1.33H, *E isomer*), 7.74 (td, *J* = 7.8, 1.9 Hz, 0.67H, *E isomer*), 7.51 (dd, *J* = 22.8, 8.2 Hz, 1H), 7.41 – 7.04 (m, 6H), 6.67 – 6.59 (m, 1H), 6.45 (d, *J* = 17.9 Hz, 0.68H, *E isomer*), 3.93 (s, 1H, *Z isomer*), 3.89 (s, 2H, *E isomer*). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 150.4,

153.8, 152.8 (d, *J* = 260.9 Hz, *Z* isomer), 152.5 (d, *J* = 248.6 Hz, *E* isomer), 151.7, 150.8, 149.6, 149.3, 140.2, 138.8 (d, *J* = 1.9 Hz), 138.7, 138.3, 138.1, 138.1, 129.9, 129.7, 128.7 (d, *J* = 8.1 Hz), 128.6, 128.4 (d, *J* = 2.9 Hz), 128.0 (d, *J* = 32.1 Hz), 125.8, 125.8, 122.7, 121.9, 120.9, 119.8, 118.9 (d, *J* = 1.2 Hz), 112.1 (d, *J* = 32.0 Hz), 108.6 (d, *J* = 9.0 Hz), 107.5 (d, *J* = 4.4 Hz), 105.7 (d, *J* = 4.6 Hz), 104.8, 104.4, 101.4, 101.4, 55.6 (*Z* isomer), 55.5 (*E* isomer),

52.2 (*Z* isomer), 52.2 (*E* isomer). (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -88.6 (dd, *J* = 17.9, 2.9 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -102.9 (d, *J* = 37.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₉FN₂O₃H [M+H]⁺ 403.1458, found: 403.1460.

Methyl 4-(2-fluoro-2-(5-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ra)



Following General Method C, **3ra** was obtained as yellow oil (0.095 mmol, 38.2 mg, 63%, *E/Z* 68/32) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. ¹H NMR (400 MHz, CDCl₃): δ 8.74 – 8.62 (m, 0.33H, *Z* isomer), 8.59 – 8.48 (m, 0.67H, *E* isomer), 8.00 (d, *J* = 8.3 Hz, 0.66H, *Z* isomer), 7.90 (td, J = 7.7, 1.9 Hz, 0.32H, *Z* isomer), 7.85 – 7.77 (m, 1.34H, *E* isomer), 7.74 (td, *J* = 7.8, 1.9 Hz, 0.68H, *E* isomer), 7.62 – 7.42 (m, 2H), 7.40 – 6.82 (m, 6H), 6.47 (d, *J* = 18.0 Hz, 0.68H, *E* isomer), 6.07 (d, J = 37.5 Hz, 0.32H, *Z* isomer), 3.95 – 3.87 (m, 6H).). ¹³C NMR (101 MHz, CDCl₃): δ 166.8, 155.5,

155.4, 152.7 (d, *J* = 259.8 Hz, *Z* isomer), 152.4 (d, *J* = 248.5 Hz, *E* isomer), 151.7, 150.8, 149.5, 149.2, 138.6, 138.2, 138.1, 138.1, 134.1, 132.6 (d, *J* = 2.0 Hz), 132.1 (d, *J* = 29.9 Hz), 129.9, 129.6, 129.5 (d, *J* = 32.0 Hz), 128.7, 128.6, 128.4, 128.4, 128.3, 122.5, 121.7, 120.5, 119.4, 115.4, 115.1, 112.8, 112.3, 112.3, 112.0, 109.7 (d, *J* = 4.6 Hz), 108.9 (d, *J* = 9.0 Hz), 108.0 (d, *J* = 5.1 Hz), 102.7, 102.5, 55.8 (*Z* isomer), 55.8 (*E* isomer), 52.2 (*Z* isomer), 52.1 (*E* isomer). (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -89.1 (dd, *J* = 17.7, 2.8 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -89.1 (dd, *J* = 4.9, 1.8 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ 8.51 (dd, *J* = 4.9, 1.8 Hz, 1H), 7.80 (d, *J* = 8.3 Hz, 2H), 7.73 (td, *J* = 7.8, 1.9 Hz, 1H), 7.57 (d, *J* = 9.1 Hz, 1H), 7.28 (s, 1H), 7.20 (ddd, *J* = 7.5, 4.9, 1.0 Hz, 1H), 7.12 (d, *J* = 8.2 Hz, 2H), 7.07 (d, *J* = 2.5 Hz, 1H), 6.96 (dd, *J* = 9.1, 2.5 Hz, 1H), 6.85 (d, *J* = 2.6 Hz, 1H), 6.46 (d, *J* = 18.0 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H).

Methyl 4-(2-fluoro-2-(6-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3sa)



Following General Method C, **3sa** was obtained as yellow oil (0.104 mmol, 41.8 mg, 69%, E/Z 68/32) using EA/PE (5%-20%) as eluent. E/Z single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer.

¹H NMR (400 MHz, CDCl₃): δ 8.76 – 8.65 (m, 0.33H, *Z* isomer), 8.61 – 8.47 (m, 0.67H, *E* isomer), 8.01 – 7.96 (m, 0.67H, *Z* isomer), 7.91 (td, *J* = 7.8, 2.0 Hz, 0.33H, *Z* isomer), 7.86 – 7.78 (m, 1.34H, *E* isomer), 7.76 (td, *J* = 7.8, 1.9 Hz, 0.7H, *E* isomer), 7.60 – 7.43 (m, 2H), 7.42 – 7.09 (m, 4H), 7.06 – 6.85 (m, 2H), 6.43 (d, *J* = 18.0 Hz, 0.68H, *E* isomer), 5.99 (d, *J* = 37.6 Hz, 0.32H, *Z* isomer),

3.94 – 3.82 (m, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 166.8, 158.5, 158.5, 152.8 (d, J = 259.7 Hz, Z isomer), 152.5 (d, J = 248.9 Hz, E isomer), 151.8, 150.9, 149.6, 149.2, 140.0, 138.7, 138.5 (d, J = 2.0 Hz), 138.3, 138.2, 138.1, 130.7 (d, J = 30.5 Hz), 129.9, 129.6, 128.6, 128.5 (d, J = 2.5 Hz), 128.5, 128.3 (d, J = 3.0 Hz), 128.0, 122.6, 122.5, 122.2, 122.0 (d, J = 1.3 Hz), 121.9, 121.8, 120.7, 119.6, 112.1, 112.0, 111.8 (d, J = 31.0 Hz), 110.2 (d, J = 4.7 Hz), 108.6 (d, J = 4.7 Hz), 108.1 (d, J = 9.4 Hz), 95.0 (*E* isomer), 94.7, 55.7(*Z* isomer and *E* isomer overlap), 52.2 (*Z* isomer), 52.1 (*E* isomer). (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -88.5 (dd, J = 18.1, 2.9 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -102.9 (d, J = 37.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₉FN₂O₃H [M+H]⁺ 403.1458, found: 403.1459. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.55 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.85 – 7.79 (m, 2H), 7.76 (td, J = 7.8, 1.9 Hz, 1H), 7.53 (d, J = 8.7 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.23 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.19 – 7.11 (m, 3H), 6.93 – 6.86 (m, 2H), 6.43 (d, J = 17.9 Hz, 1H), 3.90 (s, 3H), 3.84 (s, 3H).

Methyl 4-(2-fluoro-2-(1-(pyrimidin-2-yl)-1*H*-pyrrol-2-yl)vinyl)benzoate (3ta)



Following General Method C, **3ta** was obtained as a colourless oil of inseparable *E/Z* mixture (0.059 mmol, 19 mg, 39%, *E/Z* 75/25) using EA/PE (5%-20%) as eluent. ¹H NMR (**400 MHz**, **CDCl₃**): δ 8.66 (dd, *J* = 8.7, 4.8 Hz, 2H), 8.06 – 7.74 (m, 3H), 7.70 – 7.62 (m, 0.5H), 7.18 – 7.08 (m, 2.5H), 6.66 – 6.06 (m, 3H), 3.89 (d, *J* = 25.2 Hz, 3H). ¹³C NMR (**101 MHz, CDCl₃**): δ 167.1, 167.0, 158.5, 158.5, 156.6, 156.4, 153.9 (d, *J* = 250.3 Hz, *E isomer*), 153.7 (d, *J* = 264.2 Hz, *Z isomer*), 139.5 (d, *J* = 10.9 Hz), 139.1 (d, *J* = 4.8 Hz), 129.9, 129.6, 128.7 (d, *J* = 8.1 Hz), 128.4 (d, *J* = 3.0 Hz), 128.2 (d, *J* = 1.3 Hz), 128.2 (d, *J* = 2.9 Hz), 126.1 (d, *J* = 25.7 Hz), 124.4 (d, *J* = 1.5 Hz), 123.7 (d, *J* = 3.7 Hz), 123.3 (d, *J* = 29.8 Hz), 118.8 (d, *J* = 5.2 Hz),

118.1 (d, J = 5.5 Hz), 118.1, 118.0, 111.3 (d, J = 2.0 Hz), 110.8 (d, J = 33.7 Hz), 110.9, 107.7 (d, J = 12.0 Hz), 52.2, 52.1. *(E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -83.4 (dt, J = 16.9, 3.2 Hz, 1F), *(Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -91.6 (dd, J = 34.8, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₁₈H₁₄FN₃O₂H [M+H]⁺ 324.1148, found: 324.1151.

Dimethyl 4,4'-((1-(pyrimidin-2-yl)-1*H*-pyrrole-2,5-diyl)bis(2-fluoroethene-2,1-diyl))dibenzoate (3ta`)



Following General Method C, **3ta**` was obtained as a yellow oil of inseparable *isomer* (*EE/EZ/ZZ*) mixture (0.047 mmol, 23.2 mg, 31%, *isomer ration* 7/8/20/55) using EA/PE (15%-40%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.93 – 8.50 (m, 2H), 8.04 – 7.80 (m, 4H), 7.58 – 7.35 (m, 1H), 7.25 – 7.12 (m, 4H), 6.74 – 5.99 (m, 4H), 3.98 – 3.79 (m, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 166.9, 166.9, 158.8, 158.6, 158.3, 156.7, 156.1, 152.3 (d, *J* = 251.0 Hz), 152.0 (d, *J* = 247.3 Hz), 138.7, 138.6, 138.6, 138.6, 138.5, 138.4, 138.3, 138.3, 129.9, 129.7, 129.7, 128.7, 128.7, 128.7, 128.5, 128.4, 128.4,

126.9, 126.6, 126.6, 119.6, 119.1, 116.2, 115.8, 115.8, 114.7, 114.6, 112.1, 111.8, 111.7, 111.5, 111.4, 108.2, 108.1, 77.5, 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -88.1 (dd, J = 17.3, 2.8 Hz, 1F), -88.4 (d, J = 15.5 Hz, 1F), -99.1 (d, J = 36.6 Hz, 1F), -100.7 (d, J = 36.8 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₈H₂₁F₂N₃O₄H [M+H]⁺ 502.1578, found: 502.1573. Note: (1) *isomer ration determined by* ¹⁹F NMR *after column.* (2) ¹³C NMR *can not affiliation clearly.*

Methyl 4-(2-fluoro-2-(2-(pyrimidin-2-yl)thiophen-3-yl)vinyl)benzoate (3ua)



Following General Method C, **3ua** was obtained as a yellow oil (0.051 mmol, 17.4 mg, 34%, *E/Z* 71/29) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 15% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.63 (d, *J* = 4.9 Hz, 2H), 7.72 (d, *J* = 8.3 Hz, 2H), 7.35 (d, *J* = 5.1 Hz, 1H), 7.06 – 6.96 (m, 3H), 6.90 (dd, *J* = 5.2, 1.1 Hz, 1H), 6.48 (d, *J* = 18.4 Hz, 1H), 3.78 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 160.9, 157.2, 155.7 (d, *J* = 252.1 Hz), 143.1, 138.9 (d, *J* = 12.3 Hz), 132.4 (d, *J* = 28.6 Hz), 131.1 (d, *J* = 2.3 Hz), 129.6, 129.2, 128.4 (d, *J* = 1.4 Hz), 128.2 (d, *J* = 3.0 Hz), 119.0, 110.5 (d, *J* = 30.1 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -84.5 (d, *J* =

18.4 Hz, 1F). HRMS (ESI, m/z): calcd. for C₁₈H₁₃FN₂O₂SH [M+H]⁺ 341.0760, found: 341.0765. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, J = 4.9 Hz, 2H), 8.12 – 7.94 (m, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 5.2 Hz, 1H), 7.31 – 7.23 (m, 1H), 7.16 (t, J = 4.9 Hz, 1H), 6.27 (d, J = 37.0 Hz, 1H), 3.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 161.3, 157.2, 155.5 (d, J = 266.3 Hz), 140.9, 138.6 (d, J = 3.9 Hz), 134.1 (d, J = 134.1 Hz), 130.5 (d, J = 4.7 Hz), 129.9, 128.9 (d, J = 8.2 Hz), 128.6 (d, J = 2.5 Hz), 128.5, 118.9, 109.3 (d, J = 9.3 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -93.3 (d, J = 37.0 Hz, 1F). HRMS (ESI, m/z): calcd. for C₁₈H₁₃FN₂O₂SH [M+H]⁺ 341.0760, found: 341.0769.

Methyl 4-(2-fluoro-2-(2-(pyrimidin-2-yl)phenyl)vinyl)benzoate (3va)



Following General Method C, **3va** was obtained as yellow oil (0.035 mmol, 11.5 mg, 23%, *E/Z* 65/35) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 15% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, *J* = 4.9 Hz, 2H), 8.08 (dq, *J* = 7.9, 0.9 Hz, 1H), 7.80 – 7.70 (m, 2H), 7.63 – 7.51 (m, 1H), 7.48 – 7.38 (m, 2H), 7.17 (t, *J* = 4.9 Hz, 1H), 7.06 – 6.94 (m, 2H), 6.36 (d, *J* = 19.3 Hz, 1H), 3.85 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 165.5, 160.8 (d, *J* = 256.5 Hz), 157.1, 139.0 (d, *J* = 12.5 Hz), 138.7 (d, *J* = 0.7 Hz), 131.8 (d, *J* = 3.1 Hz), 131.4 (d, *J* = 26.2 Hz), 131.0 (d, *J* = 1.5 Hz), 130.5 (d, *J* = 2.4 Hz), 130.1

(d, J = 1.1 Hz), 129.6, 128.5 (d, J = 2.9 Hz), 128.2 (d, J = 1.1 Hz), 119.2, 109.2 (d, J = 30.4 Hz), 52.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -83.1 (d, J = 19.1 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₅FN₂O₂H [M+H]⁺ 335.1196, found: 335.1199. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.83 (d, J = 4.9 Hz, 2H), 7.96 (dd, J = 23.6, 7.9 Hz, 3H), 7.68 – 7.49 (m, 5H), 7.24 (d, J = 4.9 Hz, 1H), 6.10 (d, J = 37.0 Hz, 1H), 3.91 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.0, 165.3, 160.6 (d, J = 267.4 Hz), 157.2, 138.8 (d, J = 4.0 Hz), 137.9, 132.8 (d, J = 25.2 Hz), 131.1, 130.1, 130.0 (d, J = 4.8 Hz), 129.9, 129.7, 128.7 (d, J = 8.1 Hz), 128.5 (d, J = 2.6 Hz), 119.2, 108.5 (d, J = 9.7 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -91.7 (d, J = 37.1 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₅FN₂O₂H [M+H]⁺ 335.1196, found: 335.1206.

Methyl 4-(2-(2-(1*H*-pyrazol-1-yl)phenyl)-2-fluorovinyl)benzoate (3wa)



Following General Method C, **3wa** was obtained as a colourless oil of inseparable *E/Z* mixture (0.057 mmol, 18.4 mg, 38%, *E/Z* 40/60) using EA/PE (5%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.00 – 7.60 (m, 5H), 7.58 – 7.48 (m, 3H), 7.47 – 7.34 (m, 1H), 7.20 – 6.78 (m, 1H), 6.49 – 5.50 (m, 2H), 3.88 (d, *J* = 20.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.9, 166.8, 157.4 (d, *J* = 254.0 Hz, *E isomer*), 156.2 (d, *J* = 263.5 Hz, *Z isomer*), 141.3, 141.2, 139.8, 138.4 (d, *J* = 2.0 Hz), 138.0 (d, *J* = 3.5 Hz), 137.7 (d, *J* = 11.7 Hz), 132.0 (d, *J* = 2.1 Hz), 131.6 (d, *J* = 2.4 Hz), 130.6, 129.9, 129.8 (d, *J* = 1.7 Hz), 129.7, 129.5 (d, *J* = 5.9 Hz), 129.0 (d, *J* = 8.2 Hz), 129.0 (d, *J* = 2.3 Hz), 128.7 (d, *J* =

1.5 Hz), 128.6, 128.3 (d, J = 2.9 Hz), 128.0 (d, J = 1.5 Hz), 127.2, 126.7, 126.0 (d, J = 26.5 Hz), 125.7 (d, J = 1.1 Hz), 111.3 (d, J = 30.4 Hz), 109.9 (d, J = 8.6 Hz), 107.5 (d, J = 8.1 Hz), 52.2, 52.2. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -85.9 (d, J = 18.9 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -101.0 (d, J = 38.8 Hz, 1F). HRMS (ESI, m/z): calcd. for C₁₉H₁₅FN₂O₂H [M+H]⁺ 323.1196, found: 323.1201.

2-(1-fluoro-2-(4-methoxyphenyl)vinyl)-1-(pyrimidin-2-yl)-1*H*-indole (3ab)



Following General Method C, 3ab was obtained as colourless oil (0.090 mmol, 31.1 mg, 60%, *E/Z* 50/50) using EA/PE (2%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 10 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.73 (d, *J* = 4.8 Hz, 2H), 8.48 (dd, *J* = 8.4, 1.0 Hz, 1H), 7.56 (d, *J* = 7.8 Hz, 1H), 7.36 (ddt, *J* = 8.3, 7.1, 1.1 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.13 – 7.07 (m, 3H), 6.81 (dd, *J* = 3.6, 0.7 Hz, 1H), 6.70 – 6.64 (m, 2H), 6.42 (d, *J* = 18.9 Hz, 1H), 3.71 (s, 3H). ¹³C NMR (400 MHz, CDCl₃): δ 158.7 (d, *J* = 0.8 Hz), 158.2, 157.6, 151.1 (d, *J* = 242.3 Hz), 137.1 (d, *J* = 1.8 Hz), 130.4 (d, *J* = 28.2 Hz), 129.7 (d, *J* = 2.8 Hz), 128.8 (d, *J* = 1.6

Hz), 126.4 (d, J = 10.3 Hz), 125.1 (d, J = 0.8 Hz), 122.5, 121.6 (d, J = 1.1 Hz), 117.4, 115.0, 113.9, 112.5 (d, J = 5.8 Hz), 111.2 (d, J = 30.5 Hz), 55.3. ¹⁹F NMR (376 MHz, CDCl3): δ -94.1 (dd, J = 19.0, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₁H₁₆FN₃OH [M+H]⁺ 346.1356, found: 346.1360. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, J = 4.8 Hz, 2H), 8.40 – 8.24 (m, 1H), 7.62 (dt, J = 7.7, 1.0 Hz, 1H), 7.57 – 7.48 (m, 2H), 7.32 (ddd, J = 8.4, 7.2,

1.3 Hz, 1H), 7.26 - 7.19 (m, 1H), 7.15 (t, J = 4.8 Hz, 1H), 6.94 (dd, J = 2.5, 0.8 Hz, 1H), 6.91 - 6.84 (m, 2H), 6.21 (d, J = 36.7 Hz, 1H), 3.81 (s, 3H). ¹³**C NMR (400 MHz, CDCl₃):** δ 159.0 (d, J = 3.1 Hz), 158.4, 157.8, 150.8 (d, J = 256.1 Hz), 137.7, 132.7 (d, J = 25.4 Hz), 130.4 (d, J = 7.4 Hz), 128.7, 126.8 (d, J = 4.1 Hz), 124.9, 122.6, 121.2, 117.7, 114.1, 114.1, 110.6 (d, J = 5.4 Hz), 108.8 (d, J = 10.6 Hz), 55.43. ¹⁹F **NMR (376 MHz, CDCl₃):** δ -103.7 (dd, J = 36.7, 2.5 Hz, 1F). **HRMS (ESI, m/z):** calcd. for C₂₁H₁₆FN₃OH [M+H]⁺ 346.1356, found: 346.1359.

2-(1-fluoro-2-(3,4,5-trimethoxyphenyl)vinyl)-1-(pyrimidin-2-yl)-1*H*-indole (3ac)



Following General Method C, **3ac** was obtained as colourless oil (0.126 mmol, 51.3 mg, 84%, *E/Z* 27/73) using EA/PE (5%-40%) as eluent. *E/Z* single isomer isolated by PTLC using 15% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.66 (d, *J* = 4.8 Hz, 2H), 8.39 (d, *J* = 8.5 Hz, 1H), 7.54 (d, *J* = 7.8 Hz, 1H), 7.33 – 7.25 (m, 1H), 7.19 – 7.14 (m, 1H), 7.04 (t, *J* = 4.8 Hz, 1H), 6.87 (d, *J* = 3.4 Hz, 1H), 6.32 (d, *J* = 18.1 Hz, 1H), 6.19 (s, 2H), 3.69 (s, 3H), 3.43 (s, 6H). ¹³C NMR (400 MHz, CDCl₃): δ 158.2, 157.4, 153.0, 151.8 (d, *J* = 245.8 Hz), 137.1 (d, *J* = 1.1 Hz), 136.9 (d, *J* = 2.1 Hz), 130.0 (d, *J* = 32.0 Hz), 129.2 (d, *J* = 11.0 Hz), 128.7 (d, *J*

= 1.8 Hz), 125.3 (d, J = 1.0 Hz), 122.6, 121.6 (d, J = 1.1 Hz), 117.4, 114.9, 112.5 (d, J = 4.7 Hz), 112.0 (d, J = 31.6 Hz), 105.4 (d, J = 2.7 Hz), 61.0, 55.9. ¹⁹F NMR (376 MHz, CDCl₃): δ -91.5 (dd, J = 18.1, 3.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₂₀FN₃O₃H [M+H]⁺ 406.1567, found: 406.1569. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.35 (dd, J = 8.4, 0.9 Hz, 1H), 7.62 (dt, J = 7.8, 1.0 Hz, 1H), 7.34 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.27 - 7.21 (m, 1H), 7.17 (t, J = 4.8 Hz, 1H), 6.96 (dd, J = 2.5, 0.7 Hz, 1H), 6.83 (s, 2H), 6.19 (d, J = 35.7 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 6H). ¹³C NMR (400 MHz, CDCl₃): δ 158.4, 157.7, 153.2, 151.8 (d, J = 257.9 Hz), 137.7, 132.4 (d, J = 24.9 Hz), 129.6 (d, J = 4.3 Hz), 128.6, 125.1, 122.6, 121.3, 117.7, 114.2, 111.2 (d, J = 5.5 Hz), 109.2 (d, J = 10.1 Hz), 106.3 (d, J = 8.3 Hz), 61.1, 56.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -101.4 (dd, J = 35.7, 2.7 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₃H₂₀FN₃O₃H [M+H]⁺ 406.1567, found: 406.1567.

2-(1-fluoro-2-(naphthalen-2-yl)vinyl)-1-(pyrimidin-2-yl)-1H-indole (3ad)



Following General Method C, **3ad** was obtained as yellow oil (0.113 mmol, 41.3 mg, 75%, E/Z 19/81) using EA/PE (2%-20%) as eluent. E/Z single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, J = 4.8 Hz, 2H), 8.54 (dd, J = 8.5, 1.0 Hz, 1H), 7.75 – 7.65 (m, 3H), 7.55 (t, J = 8.4 Hz, 2H), 7.44 – 7.32 (m, 4H), 7.26 – 7.21 (m, 1H), 7.13 (t, J = 4.8 Hz, 1H), 6.84 (dd, J = 3.6, 0.8 Hz, 1H), 6.65 (d, J = 18.7 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.2, 157.6, 152.7 (d, J = 244.2 Hz), 137.2 (d, J = 1.6 Hz), 133.5, 132.5, 131.7 (d, J = 10.7 Hz), 130.3, 130.0, 128.8 (d, J = 1.1 Hz), 128.0 (d, J = 7.0 Hz), 127.8 (d, J = 4.1 Hz), 127.7, 126.4

(d, J = 1.8 Hz), 126.2, 125.9, 125.3 (d, J = 0.9 Hz), 122.5, 121.7, 117.4, 115.0, 113.2 (d, J = 5.6 Hz), 111.7 (d, J = 31.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -91.7 (dd, J = 18.8, 3.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₆FN₃H [M+H]⁺ 366.1407, found: 366.1400. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.38 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H), 7.88 – 7.72 (m, 4H), 7.66 (d, J = 7.7 Hz, 1H), 7.46 (tt, J = 5.7, 4.6 Hz, 2H), 7.37 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.31 – 7.22 (m, 1H), 7.15 (t, J = 4.8 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 6.45 (d, J = 36.3 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.4, 157.8, 152.4 (d, J = 259.3 Hz), 137.8, 133.6, 132.7, 132.4, 131.6 (d, J = 4.4 Hz), 128.7, 128.3, 128.1, 128.1, 127.7, 127.0 (d, J = 8.0 Hz), 126.3 (d, J = 15.0 Hz), 125.1, 122.7, 121.4, 117.7, 114.2, 111.2 (d, J = 5.4 Hz), 109.3 (d, J = 10.2 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -100.2 (dd, J = 36.2, 2.4 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₄H₁₆FN₃H [M+H]⁺ 366.1407, found: 346.1405.

2-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-fluorovinyl)-1-(pyrimidin-2-yl)-1H-indole (3ae)



Following General Method C, **3ae** was obtained as a colourless oil of inseparable *E/Z* mixture (0.113 mmol, 41.9 mg, 75%, *E/Z* 35/65) using EA/PE (2%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.76 (dd, *J* = 13.7, 4.8 Hz, 2H), 8.43 (ddd, *J* = 71.7, 8.5, 0.9 Hz, 1H), 7.70 – 7.51 (m, 1H), 7.41 – 7.31 (m, 1H), 7.30 – 7.18 (m, 2H), 7.14 (dt, *J* = 20.4, 4.8 Hz, 1H), 7.09 – 6.93 (m, 1H), 6.89 – 6.82 (m, 1H), 6.79 – 6.61 (m, 1H), 6.45 – 6.07 (m, 1H), 4.31 – 4.11 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.4, 158.2, 157.8, 157.6, 151.5 (d, *J* = 243.2 Hz, *E*), 151.1 (d, *J* = 256.2 Hz, *Z*), 143.5, 143.3, 143.2 (d, *J* = 2.9 Hz), 142.8 (d, *J* = 1.0 Hz), 137.7, 137.1 (d, *J* = 1.8 Hz), 132.7 (d, *J* = 25.4 Hz), 130.2 (d, *J* = 29.1 Hz), 128.8

(d, J = 1.6 Hz), 128.7, 127.6 (d, J = 4.1 Hz), 127.4 (d, J = 10.6 Hz), 125.1 (d, J = 1.1 Hz), 124.9, 122.7, 122.6, 122.5, 122.4, 122.0 (d, J = 2.8 Hz), 121.6 (d, J = 1.1 Hz), 121.3, 117.7, 117.7, 117.6, 117.4, 117.3, 117.2, 115.0, 114.1, 112.7 (d, J = 5.7 Hz), 111.1, 110.8, 110.7 (d, J = 5.7 Hz), 108.7 (d, J = 10.2 Hz), 64.6, 64.5, 64.5, 64.3. (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -93.2 (dd, J = 19.0, 3.6 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): -102.7 (dd, J = 36.2, 2.4 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₆FN₃O₂H [M+H]⁺ 374.1305, found: 374.1310.

4-(2-fluoro-2-(1-(pyrimidin-2-yl)-1*H*-indol-2-yl)vinyl)-*N*,*N*-diphenylaniline (3af)



Following General Method C, **3af** was obtained as yellow solid (0.123 mmol, 59.5 mg, 82%, E/Z 53/47) using EA/PE (2%-20%) as eluent. E/Z single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer, but *E* isomer convert to *Z* isomer slowly even though at -10 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.78 (dd, J = 20.7, 4.8 Hz, 2H), 8.43 (dd, J = 62.8, 8.3 Hz, 1H), 7.63 (dd, J = 14.3, 7.8 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.36 (q, J = 8.1 Hz, 1H), 7.31 – 7.16 (m, 6H), 7.13 (d, J = 7.7 Hz, 3H), 7.10 – 6.96 (m, 6H), 6.95 – 6.80 (m, 1H), 6.52 – 6.12 (m, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.4, 158.2, 157.8, 157.6, 151.3 (d, J = 243.2 Hz, *E*), 151.2 (d, J = 256.7 Hz, *Z*), 147.6, 147.6, 147.1 (d,

J = 2.9 Hz), 146.7 (d, *J* = 0.9 Hz), 137.7, 137.1 (d, *J* = 1.7 Hz), 132.8 (d, *J* = 27.3 Hz), 130.4 (d, *J* = 29.0 Hz), 129.9 (d, *J* = 8.0 Hz), 129.4, 129.3, 129.2 (d, *J* = 2.7 Hz), 128.8 (d, *J* = 1.4 Hz), 128.7, 128.1 (d, *J* = 4.4 Hz), 127.7 (d, *J* = 10.3 Hz), 125.1, 124.9, 124.7, 124.6, 123.4, 123.2, 123.2, 123.1, 122.6, 122.5, 121.6, 121.2, 117.7, 117.3, 115.0, 114.1, 112.6 (d, *J* = 5.6 Hz), 111.4 (d, *J* = 31.0 Hz), 110.7 (d, *J* = 4.8 Hz), 108.9 (d, *J* = 10.4 Hz). *(E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -93.0 (dd, *J* = 19.0, 3.7 Hz, 1F). *(Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -102.7 (dd, *J* = 36.7, 2.4 Hz, 1F). HRMS (ESI, m/z): calcd. for $C_{32}H_{23}FN_{4}H$ [M+H]⁺ 483.1985, found: 483.1990. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.81 (d, *J* = 4.8 Hz, 2H), 8.34 (dd, *J* = 8.4, 0.9 Hz, 1H), 7.64 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.54 - 7.43 (m, 2H), 7.35 (ddd, *J* = 8.4, 7.1, 1.3 Hz, 1H), 7.31 - 7.27 (m, 3H), 7.26 - 7.23 (m, 2H), 7.19 (t, *J* = 4.8 Hz, 1H), 7.15 - 7.10 (m, 4H), 7.08 - 7.01 (m, 4H), 6.97 (d, *J* = 2.3 Hz, 1H), 6.24 (d, *J* = 36.7 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.4, 157.8, 151.1 (d, *J* = 258.7 Hz), 147.6, 147.0 (d, *J* = 2.9 Hz), 137.7, 132.8, 132.6, 129.9 (d, *J* = 8.0 Hz), 129.4, 128.7, 128.1 (d, *J* = 4.6 Hz), 124.9, 124.7, 123.3 (d, *J* = 14.0 Hz), 122.6, 121.2, 117.7, 114.0, 110.7 (d, *J* = 5.0 Hz), 108.8 (d, *J* = 10.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -102.7 (dd, *J* = 36.7, 2.4 Hz, 1F). HRMS (ESI, m/z): calcd. for $C_{32}H_{23}FN_{4}H$ [M+H]⁺ 483.1986.

2-(2-(4-chlorophenyl)-1-fluorovinyl)-1-(pyrimidin-2-yl)-1*H*-indole (3ag)



Following General Method C, **3ag** was obtained as yellow oil (0.108 mmol, 37.8 mg, 72%, E/Z 74/26) using EA/PE (2%-20%) as eluent. E/Z single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, **CDCl**₃): δ 8.74 (d, J = 4.8 Hz, 2H), 8.51 (dd, J = 8.5, 1.0 Hz, 1H), 7.56 (dd, J = 7.9, 1.2 Hz, 1H), 7.38 (ddt, J = 8.3, 7.1, 1.1 Hz, 1H), 7.28 – 7.20 (m, 1H), 7.18 – 7.06 (m, 5H), 6.79 (dd, J = 3.5, 0.8 Hz, 1H), 6.41 (d, J = 18.1 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.3, 157.5, 152.7 (d, J = 246.2 Hz), 137.1 (d, J = 1.8 Hz), 132.7, 132.7 (d, J = 1.4 Hz), 132.6 (d, J = 10.8 Hz), 129.9 (d, J = 3.0 Hz), 128.7 (d, J = 1.6 Hz), 128.6, 125.4 (d, J = 1.1 Hz), 122.6,

121.7 (d, J = 1.1 Hz), 117.4, 115.0, 112.9 (d, J = 6.0 Hz), 110.3 (d, J = 31.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ - 90.8 (dd, J = 18.0, 3.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₃ClFN₃H [M+H]⁺ 350.0860, found: 350.0874. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 8.4, 1.0 Hz, 1H), 7.64 (dt, J = 7.8, 1.0 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.39 – 7.30 (m, 3H), 7.28 – 7.23 (m, 1H), 7.18 (t, J = 4.8 Hz, 1H), 7.00 (dd, J = 2.6, 0.8 Hz, 1H), 6.24 (d, J = 35.7 Hz, 1H). ¹³C NMR (400 MHz, CDCl₃): δ 158.4, 157.7, 152.6 (d, J = 259.4 Hz), 137.7, 133.0 (d, J = 3.4 Hz), 132.5 (d, J = 4.2 Hz), 132.1 (d, J = 25.3 Hz), 130.2, 132.0, 128.8, 125.3, 122.7, 121.4, 117.7, 114.2, 111.4 (d, J = 5.6 Hz), 108.1 (d, J = 10.2 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -99.5 (dd, J = 35.5, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₃ClFN₃H [M+H]⁺ 350.0860, found: 350.0863.

2-(2-(4-bromophenyl)-1-fluorovinyl)-1-(pyrimidin-2-yl)-1*H*-indole (3ah)



Following General Method C, **3ah** was obtained as yellow oil (0.113 mmol, 44.1 mg, 75%, *E/Z* 75/25) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, J = 4.8 Hz, 2H), 8.52 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.39 (ddt, J = 8.4, 7.2, 1.1 Hz, 1H), 7.30 – 7.20 (m, 3H), 7.13 (t, J = 4.8 Hz, 1H), 7.10 – 7.04 (m, 2H), 6.80 (d, J = 3.5 Hz, 1H), 6.40 (d, J = 18.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 158.2, 157.5, 152.8 (d, *J* = 246.5 Hz), 137.2 (d, *J* = 1.8 Hz), 133.2 (d, *J* = 10.5 Hz), 131.6, 130.2 (d, *J* = 3.0 Hz), 129.7 (d, *J* = 27.9 Hz), 128.7 (d, *J* = 1.5 Hz), 125.4 (d, *J*

= 1.1 Hz), 122.7, 121.7, 120.9 (d, J = 1.1 Hz), 117.4, 115.0, 112.9 (d, J = 6.0 Hz), 110.4 (d, J = 31.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -90.5 (dd, J = 18.1, 3.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₃BrFN₃H [M+H]⁺ 394.0355, found: 394.0356. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 8.5, 1.0 Hz, 1H), 7.64 (dt, J = 7.8, 1.0 Hz, 1H), 7.54 – 7.41 (m, 4H), 7.36 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.31 – 7.21 (m, 1H), 7.17 (t, J = 4.8 Hz, 1H), 7.00 (dd, J = 2.5, 0.8 Hz, 1H), 6.23 (d, J = 35.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 158.4, 157.7, 152.7 (d, J = 258.8 Hz), 137.8, 132.9 (d, J = 4.3 Hz), 132.2 (d, J = 25.4 Hz), 131.8, 130.5 (d, J = 8.2 Hz), 128.6, 125.3, 122.7, 121.4, 121.2 (d, J = 3.5 Hz), 117.7, 114.3, 111.4 (d, J = 6.1 Hz), 108.1 (d, J = 10.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -99.2 (dd, J = 36.1, 2.7 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₃BrFN₃H [M+H]⁺ 394.0355, found: 394.0375.

2-(1-fluoro-2-(4-(trifluoromethyl)phenyl)vinyl)-1-(pyrimidin-2-yl)-1H-indole (3ai)



Following General Method C, **3ai** was obtained as yellow oil (0.075 mmol, 28.9 mg, 50%, *E/Z* 76/24) using EA/PE (2%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 2% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, *J* = 4.8 Hz, 2H), 8.56 (dd, *J* = 8.5, 1.0 Hz, 1H), 7.63 – 7.56 (m, 1H), 7.41 (dd, *J* = 8.5, 7.1 Hz, 3H), 7.32 (d, *J* = 8.2 Hz, 2H), 7.30 – 7.23 (m, 1H), 7.15 (t, *J* = 4.8 Hz, 1H), 6.82 (dd, *J* = 3.6, 0.7 Hz, 1H), 6.50 (d, *J* = 17.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 158.3, 157.5, 153.9 (d, *J* = 251.8 Hz), 138.1 (d, *J* = 1.4 Hz), 138.0 (d, *J* = 1.4 Hz), 137.2 (d, *J* = 1.6 Hz), 129.5 (d, *J* = 28.0 Hz), 129.0 (d, *J* = 1.1 Hz), 128.8 (d, *J* = 3.0 Hz), 128.7 (d, *J* =

1.7 Hz), 125.6 (q, J = 2.3 Hz), 125.4 (q, J = 4.0 Hz), 122.7, 121.8 (d, J = 1.2 Hz), 117.5, 115.2, 113.3 (d, J = 6.0 Hz), 110.3 (d, J = 31.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -62.6 (s, 3F), δ -88.3 (dd, J = 17.8, 3.7 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₁H₁₃F₄N₃H [M+H]⁺ 384.1124, found: 384.1134. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.79 (d, J = 4.8 Hz, 2H), 8.41 (dt, J = 8.4, 0.9 Hz, 1H), 7.73 – 7.57 (m, 5H), 7.39 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.32 – 7.24 (m, 1H), 7.18 (t, J = 4.8 Hz, 1H), 7.04 (dd, J = 2.5, 0.8 Hz, 1H), 6.32 (d, J = 35.3 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 158.4, 157.7, 153.8 (d, J = 263.0 Hz), 137.9, 137.6 (m), 131.9 (d, J = 25.0 Hz), 129.2 (d, J =2.7 Hz), 129.1 (d, J = 8.2 Hz), 128.9 (d, J = 2.6 Hz), 128.5, 125.6 (q, J = 3.8 Hz), 124.4 (q, J = 271.3 Hz), 122.8, 121.5, 117.7, 114.4, 111.8 (d, J = 5.5 Hz), 107.9 (d, J = 9.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ -62.5 (s, 3F), δ -97.0 (dd, J = 35.4, 2.5 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₁H₁₃F₄N₃H [M+H]⁺ 384.1124, found: 384.1129.

2-(2-(2-bromophenyl)-1-fluorovinyl)-1-(pyrimidin-2-yl)-1H-indole (3aj)



Following General Method C, **3aj** was obtained as a colourless oil of inseparable *E/Z* mixture (0.053 mmol, 20.9 mg, 35%, *E/Z* 39/61) using EA/PE (2%-20%) as eluent. ¹H NMR (400 MHz, CDCl₃): δ 8.76 (dd, *J* = 22.1, 4.8 Hz, 2H), 8.39 (ddd, *J* = 14.3, 8.5, 0.9 Hz, 1H), 7.95 – 7.14 (m, 6H), 7.13 – 6.74 (m, 3H), 6.68 – 6.51 (m, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 158.4, 158.2, 157.7, 157.4, 153.4 (d, *J* = 248.9 Hz), 153.0 (d, *J* = 260.3 Hz), 137.9, 137.3 (d, *J* = 1.7 Hz), 134.7 (d, *J* = 11.4 Hz), 133.6 (d, *J* = 4.4 Hz), 133.0, 132.3, 132.1 (d, *J* = 26.3 Hz), 131.1 (d, *J* = 1.1 Hz), 130.6 (d, *J* = 12.9 Hz), 129.7 (d, *J* = 30.0 Hz), 128.7 (d, *J* = 1.8 Hz), 128.6, 128.6, 127.5, 127.4, 125.3

(d, J = 3.3 Hz), 124.2 (d, J = 4.3 Hz), 123.8 (d, J = 1.4 Hz), 122.7, 122.5, 121.6 (d, J = 0.7 Hz), 121.5, 117.7, 117.4, 114.7, 114.3, 113.0 (d, J = 5.0 Hz), 111.7 (d, J = 5.0 Hz), 110.7 (d, J = 32.0 Hz), 107.6 (d, J = 9.0 Hz). (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -92.4 (dd, J = 17.2, 3.1 Hz, 1F), (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -100.6 (dd, J = 35.4, 2.3 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₀H₁₃BrFN₃H [M+H]⁺ 394.0355, found: 394.0360.

Methyl 2-(2-fluoro-2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3ak)



Following General Method C, **3ak** was obtained as yellow oil (0.086 mmol, 32.1 mg, 57%, *E/Z* 29/81) using EA/PE (5%-20%) as eluent. *E/Z* single isomer isolated by PTLC using 5% EtOAc/PE as eluent (repeat 6 times) to get the single isomer. *E* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, *J* = 4.8 Hz, 2H), 8.42 (dd, *J* = 8.5, 0.9 Hz, 1H), 7.91 (dd, *J* = 7.2, 2.1 Hz, 1H), 7.49 (d, *J* = 7.8 Hz, 1H), 7.39 (dd, *J* = 6.9, 2.1 Hz, 1H), 7.33 (ddt, *J* = 8.2, 7.1, 1.0 Hz, 1H), 7.23 – 7.17 (m, 3H), 7.14 (t, *J* = 4.8 Hz, 1H), 7.08 (d, *J* = 17.6 Hz, 1H), 6.61 (dd, *J* = 3.1, 0.8 Hz, 1H), 3.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ

167.6, 158.2, 157.6, 152.6 (d, J = 246.2 Hz), 137.2 (d, J = 1.1 Hz), 136.1 (d, J = 11.4 Hz), 132.2, 131.7 (d, J = 1.2 Hz), 130.5, 130.0, 129.0 (d, J = 3.6 Hz), 128.7, 127.0, 125.1, 122.4, 121.6, 117.4, 114.6, 113.3 (d, J = 5.4 Hz), 111.4 (d, J = 31.8 Hz), 52.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -94.3 (dd, J = 17.7, 3.2 Hz, 1F). HRMS (ESI, m/z): calcd.

for C₂₂H₁₆FN₃O₂H [M+H]⁺ 374.1305, found: 374.1318. *Z* isomer: ¹H NMR (400 MHz, CDCl₃): δ 8.83 – 8.70 (m, 2H), 8.41 – 8.28 (m, 1H), 8.01 – 7.83 (m, 2H), 7.67 – 7.57 (m, 1H), 7.48 (td, *J* = 7.7, 1.5 Hz, 1H), 7.30 (dtd, *J* = 16.7, 7.4, 1.3 Hz, 2H), 7.25 – 7.18 (m, 2H), 7.14 (t, *J* = 4.8 Hz, 1H), 7.09 – 7.05 (m, 1H), 3.88 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 167.9, 158.3, 157.8, 152.4 (d, *J* = 259.3 Hz), 137.8, 134.6 (d, *J* = 3.4 Hz), 132.5 (d, *J* = 26.7 Hz), 132.0, 130.8, 130.7 (d, *J* = 11.0 Hz), 128.8, 128.7, 127.1 (d, *J* = 0.9 Hz), 125.1, 122.6, 121.4, 117.6, 114.3, 111.6 (d, *J* = 5.5 Hz), 106.8 (d, *J* = 8.0 Hz), 52.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -102.28 (dd, *J* = 35.7, 2.6 Hz, 1F). HRMS (ESI, m/z): calcd. for C₂₂H₁₆FN₃O₂H [M+H]⁺ 374.1305, found: 374.1309.

Methyl 3-(2-fluoro-2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)vinyl)benzoate (3al)



Following General Method C, **3al** was obtained as a yellow oil of inseparable E/Z mixture (0.084 mmol, 31.5 mg, 56%, E/Z 70/30) using EA/PE (2%-20%) as eluent. ¹H **NMR (400 MHz, CDCl₃):** δ 8.74 (dd, J = 17.5, 4.8 Hz, 2H), 8.54 – 8.16 (m, 1H), 7.96 – 7.72 (m, 2H), 7.67 – 7.49 (m, 1H), 7.46 – 7.31 (m, 2H), 7.28 – 7.06 (m, 3H), 6.88 (ddd, J = 89.5, 3.0, 0.8 Hz, 1H), 6.48 (d, J = 17.8 Hz, 0.7H, E isomer), 6.30 (d, J = 35.6 Hz, 0.3H, Z isomer), 3.90 (s, 0.9H, Z isomer), 3.80 (s, 2.1H, E isomer). ¹³C **NMR (101 MHz, CDCl₃):** δ 167.1, 167.0 (E), 158.4, 158.2 (E), 157.7, 157.5 (E), 153.2 (d, J = 274.5 Hz, E), 153.0 (d, J = 260.1 Hz, Z), 137.8, 137.2 (d, J = 1.7 Hz), 134.6 (d, J

= 10.5 Hz), 134.4 (d, J = 4.1 Hz), 133.2 (d, J = 8.8 Hz), 132.7 (d, J = 2.2 Hz), 132.1 (d, J = 25.2 Hz), 130.6, 130.4, 130.1 (d, J = 7.7 Hz), 130.0 (d, J = 3.3 Hz), 129.7 (d, J = 28.5 Hz), 128.8, 128.7 (d, J = 1.7 Hz), 128.6, 128.5, 128.4 (d, J = 2.1 Hz), 128.1 (d, J = 1.0 Hz), 125.4 (d, J = 1.0 Hz), 125.3, 122.7, 122.6, 121.7 (d, J = 0.9 Hz), 121.4, 117.7, 117.4, 115.1, 114.3, 113.1 (d, J = 5.4 Hz), 111.5 (d, J = 5.5 Hz), 110.6 (d, J = 32.0 Hz), 108.3 (d, J = 10.2 Hz), 52.3, 52.2 (*E*). (*E* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, 3.5 Hz, 1F). (*Z* isomer) ¹⁹F NMR (376 MHz, CDCl₃): δ -90.4 (dd, J = 17.8, δ -90.4 [M+H]⁺ 374.1305, found: 374.1314.

6. References

(1) (a) L. Ackermann, A. V. Lygin, Org. Lett. 2011, 13, 3332–3335. (b) P. Lu, C. Feng, T.-P. Loh, Org. Lett. 2015, 17, 3210 – 3213.

(2) P. Tian, C. Feng, T.-P. Loh, Nat. Commun. 2015, 6, 7472-7478.

(3) K. Billingsley, S. L. Buchwald, J. Am. Chem. Soc. 2007, 129, 3358-3366.

(4) B. Zhou, Y. Hu, C. Wang, Angew. Chem. Int. Ed. 2015, 54, 13659-13663.

(5) J. J. Maresh, L.-A. Giddings, A. Friedrich, E. A. Loris, S. Panjikar, B. L. Trout, J. Stöckigt, B. Peters, S. E.

O'Connor, J. Am. Chem. Soc. 2008, 130, 710-723.

(6) W. Liu, S. C. Richter, Y. Zhang, L. Ackermann, Angew. Chem. Int. Ed. 2016, 55, 7747 -7750.

(7) M. L. N. Rao, P. Dasgupta, RSC Adv. 2015, 5, 65462-65470.

(8) X. Lei, G. Dutheuil, X. Pannecoucke, J.-C. Quirion, Org. Lett. 2004, 6, 2101-2104.



f1 (ppm)





f1 (ppm)



90 80 f1 (ppm)





f1 (ppm)


























-85 -87 -88 -92 f1 (ppm) -96 -86 -89 -90 -91 -93 -94 -95 -97 -98 -99





f1 (ppm)



-98.1 -98.1 -98.1 -98.2





























60





(66.8 (55.5) (55.5) (55.5) (55.5) (51.1) (51



-80 -81 -82 -83 -84 -85 -86 -87 -88 -89 -90 -91 -92 -93 -94 -95 -96 -99 -100 -101 -102 -103 -104 -105 -106 -107 -108 -109 -110 -111 -11 f1 (ppm)







-79 -80 -81 -82 -83 -84 -85 -86 -87 -88 -89 -90 -91 -92 -93 -94 -95 -96 -97 -98 -99 -100 -101 -102 -103 -104 -105 -106 -107 -108 -109 -111 -1 f1 (ppm)













f1 (ppm)





f1 (ppm)







f1 (ppm)
















157.8 157.8 157.8 157.8 137.8 137.8 137.8 137.8 137.8 137.8 137.8 137.8 137.8 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.6 137.7 137.6 137.7 137.6 137.7 137.6 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1 128.1







f1 (ppm)



--102.6 --102.6 --102.7 --102.7







158:2 157:5 157:5 137:2 137:2 137:2 133:1 133:2 133:2 133:2 133:2 133:2 133:2 133:2 135:5 135:5 135:5 135:5 135:5 135:5 135:5 135:5 135:5 135:5 135:5 135:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 125:5 121:7 121:7 121:7 121:7 121:7 110:5























